[
      {
            "id": 1,
            "name": "Benzodiazepines",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide-4a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 263,
                                    "x": 292,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 280,
                                    "x": 203,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 209,
                                    "x": 266,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 317,
                                    "x": 154,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 411,
                                    "x": 288,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C2",
                                    "y": 375,
                                    "x": 340,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              },
                              {
                                    "name": "C3",
                                    "y": 245,
                                    "x": 354,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C4",
                                    "y": 466,
                                    "x": 288,
                                    "size": 25,
                                    "color": "darkgoldenrod",
                                    "text": "steric repulsion occurs with para substituent"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide-4b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 291,
                                    "x": 292,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 305,
                                    "x": 203,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 241,
                                    "x": 266,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 345,
                                    "x": 159,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 440,
                                    "x": 291,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C2",
                                    "y": 410,
                                    "x": 340,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              },
                              {
                                    "name": "C3",
                                    "y": 273,
                                    "x": 356,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C4",
                                    "y": 490,
                                    "x": 288,
                                    "size": 25,
                                    "color": "darkgoldenrod",
                                    "text": "steric repulsion occurs with para substituent"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Lorazepam to learn about the SAR Characteristics",
                        "imagePath" : "slide-5a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 227,
                                    "x": 209,
                                    "size": 30,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 158,
                                    "x": 291,
                                    "size": 30,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 164,
                                    "x": 223,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 264,
                                    "x": 159,
                                    "size": 30,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 310,
                                    "x": 263,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              },
                              {
                                    "name": "C3",
                                    "y": 202,
                                    "x": 335,
                                    "size": 25,
                                    "color": "purple",
                                    "text": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation."
                              },
                              {
                                    "name": "C2",
                                    "y": 279,
                                    "x": 319,
                                    "size": 25,
                                    "color": "brown",
                                    "text": "F or Cl substitution reduces aromatic hydroxylation and improves half-life"
                              }
                        ],
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Ring A", "description" : "Ring A: Pi-Pi stacking with BZR" },
                              {"color": "orange", "location": "C7", "description" : "C7: EWG increases activity" },
                              {"color": "green", "location": "Ring B", "description" : "Ring B:  H-bond acceptor (O, N, S) or N-heterocycle required 1,2 annelation (N-heterocycle) increases affinity for BZR" },
                              {"color": "blue", "location": "N1", "description" : "N1: methyl group preferred; bulky group decreases activity because it prevents binding to BZR" },
                              {"color": "purple", "location": "C3", "description" : "C3: OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation." },
                              {"color": "deeppink", "location": "Ring C", "description" : "Ring C: Hydrophobic interaction with BZR" },
                              {"color": "darkgoldenrod", "location": "C4", "description" : "C4: Steric repulsion occurs with para substituent " },
                              {"color": "teal", "location": "C2", "description" : "C2:  F or Cl substitution reduces aromatic hydroxylation and improves half-life" }
                        ]
                  },
                  {
                        "title":"SAR Requirements",
                        "name" : "Hover over Alprazolam to learn about the SAR Characteristics",
                        "imagePath" : "slide-5b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ring A",
                                    "y": 276,
                                    "x": 229,
                                    "size": 50,
                                    "color": "red",
                                    "text": "Pi-Pi stacking with BZR"
                              },
                              {
                                    "name": "Ring B",
                                    "y": 197,
                                    "x": 303,
                                    "size": 50,
                                    "color": "green",
                                    "text": "H-bond acceptor (O, N, S) or N-heterocycle required. 1,2 annelation (N-heterocycle) increases affinity for BZR"
                              },
                              {
                                    "name": "N1",
                                    "y": 178,
                                    "x": 223,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Methyl group preferred; bulky group decreases activity because it prevents binding to BZR"
                              },
                              {
                                    "name": "C7",
                                    "y": 328,
                                    "x": 165,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "EWG increases activity"
                              },
                              {
                                    "name": "Ring C",
                                    "y": 384,
                                    "x": 300,
                                    "size": 50,
                                    "color": "deeppink",
                                    "text": "Hydrophobic interaction with BZR"
                              }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",
                        "name" : "Activity Change",
                        "imagePath" : "slide7-transition.jpg",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase",
                              "Decrease",
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Addition of a bulky group at N1 prevents binding to the BZR; methyl group is preferred"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide8.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Addition of Cl to position 2 reduces aromatic hydroxylation (phase one P450 metabolism) and increases half-life"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide10.PNG",
                        "question" : "Which of these 3 compounds would be the best benzodiazepine for use as a hypnotic?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "It already has the hydroxyl handle (position 3) so it is quickly metabolized to an inactive metabolite by conjugation; thus it has a short elimination half-life, which is ideal for hypnotics"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide11.PNG",
                        "question" : "Which of these 3 compounds would be the best benzodiazepine for use as an anxiolytic?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "The compound is slowly absorbed because it has a carboxylic acid that must be cleaved first (like a prodrug) and it is metabolized to an active metabolite; thus it has a long elimination half-life (40-50 hr), which is ideal for anxiolytics"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide13.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compounds (2, 3) and Conjugated Products",
                        "options" : [ 
                              "Active, Active, Inactive",
                              "Active, Inactive, Inactive", 
                              "Inactive, Inactive, Active",
                              "Inactive, Active, Inactive"
                        ],
                        "answer" : "Active, Active, Inactive",
                        "explanation" : ""
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide14.PNG",
                        "question" : "Would compound 1 (temazepam) be an ideal hypnotic or anxiolytic? Predict whether the metabolites will be active or inactive for compound 2",
                        "options" : [
                              "Anxiolytic, Active",
                              "Anxiolytic, Inactive",
                              "Hypnotic, Inactive",
                              "Hypnotic, Active"
                        ],
                        "answer" : "Hypnotic, Inactive",
                        "explanation" : ""
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide15.PNG",
                        "question" : "Would compound 1 (triazolam) be an ideal hypnotic or anxiolytic? Predict whether the metabolites will be active or inactive for the compounds (2, 3) and Conjugated Products",
                        "options" : [
                              "Anxiolytic, Active, Inactive, Inactive",
                              "Anxiolytic, Inactive, Active, Inactive",
                              "Hypnotic, Inactive, Active, Inactive",
                              "Hypnotic, Active, Inactive, Inactive"
                        ],
                        "answer" : "Hypnotic, Inactive, Active, Inactive",
                        "explanation" : ""
                  }
            ], 
            "testItems":[
                  {
                        "title":"Side-Effects",  
                        "question" : "Benzodiazepines act at _______ receptor to increase _______ channel opening:",
                        "options" : [ 
                              "GABA, Ca2+",
                              "GABA, Na+",
                              "GABA, Cl-",
                              "glutamate, Ca2+",
                              "glutamate, Na+",
                              "glutamate, Cl-"
                        ],
                        "answer" : "GABA, Cl-"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Benzodiazepines will be affected by the inhibitors or activators of",
                        "options" : [
                              "CYP2B6", 
                              "CYP3A4", 
                              "CYP2C9",
                              "C3PO"
                        ],
                        "answer" : "CYP3A4"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Diazepam and ______ are useful to treat withdrawal from _______",
                        "options" : [
                              "clonazepam, nicotine", 
                              "clonazepam, alcohol", 
                              "triazolam, opioids",
                              "triazolam, nicotine",
                              "midazolam, alcohol",
                              "midazolam, opioids",
                              "lorazepam, nicotine",
                              "lorazepam, alcohol"
                        ],
                        "answer" : "lorazepam, alcohol"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Lorazepam, ______, and ______ are all used to treat status epilepticus",
                        "options" : [
                              "clonazepam, midazolam", 
                              "clonazepam, triazolam", 
                              "diazepam, clonazepam",
                              "diazepam, midazolam"
                        ],
                        "answer" : "diazepam, clonazepam"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Patient Smith has been prescribed a benzodiazepine and another medication for OCD. Smith feels excessively sleepy and has noticed her balance is off. Smith is probably taking diazepam and",
                        "options" : [
                              "bupropion",
                              "nortriptyline",
                              "fluoxetine"
                        ],
                        "answer" : "bupropion"
                  },
                  {
                        "title":"Contraindication",  
                        "question" : "This benzodiazepine is best suited for elderly individuals with liver damage:",
                        "options" : [
                              "Lorazepam", 
                              "Diazepam", 
                              "Clonazepam"
                        ],
                        "answer" : "Lorazepam"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "An individual who takes benzodiazepine usually develops tolerance to",
                        "options" : [
                              "sedative effects", 
                              "anxiolytic effects", 
                              "anesthetic effects"
                        ],
                        "answer" : "sedative effects"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "When a benzodiazepine is taken for sleep, benzodiazepine's long elimination half life can cause:",
                        "options" : [
                              "headache", 
                              "insomnia", 
                              "grogginess",
                              "amnesia"
                        ],
                        "answer" : "grogginess"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "A serious and unusual side effect of a benzodiazepine is",
                        "options" : [
                              "Induction of P450s", 
                              "G6P deficiency", 
                              "amnesia"
                        ],
                        "answer" : "amnesia"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "An individual who takes benzodiazepine rarely develops tolerance to",
                        "options" : [
                              "sedative effects", 
                              "anxiolytic effects", 
                              "anesthetic effects"
                        ],
                        "answer" : "anxiolytic effects"
                  }
            ],
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Diazepam", "imagePath": "diazepam.PNG" },
                              {"title": "Lorazepam", "imagePath": "lorazepam.PNG" }, 
                              {"title": "Temazepam", "imagePath": "temazepam.PNG" },
                              {"title": "Triazolam", "imagePath": "triazolam.PNG" },
                              {"title": "Midazolam", "imagePath": "midazolam.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "" },
                              {"title": "Distribution", "content": "" }, 
                              {"title": "Metabolism", "content": "" },
                              {"title": "Excretion", "content": ""  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa.PNG" },
                              {"title": "Mechanism of Action", "content": "" },
                              {"title": "Pharmacological Action", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Diazepam (Long Acting)", "imagePath": "diazepam.PNG" },
                              {"title": "Lorazepam (Intermediate Acting)", "imagePath": "lorazepam.PNG" }, 
                              {"title": "Temazepam (Intermediate Acting)", "imagePath": "temazepam.PNG" },
                              {"title": "Triazolam (Short Acting)", "imagePath": "triazolam.PNG" },
                              {"title": "Midazolam (Short Acting)", "imagePath": "midazolam.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Ring A", "content": "Pi-Pi stacking with BZR" },
                              {"title": "C7", "content": "EWG increases activity" }, 
                              {"title": "Ring B", "content": "H-bond acceptor (O, N, S) or N-heterocycle required 1,2 annelation (N-heterocycle) increases affinity for BZR" },
                              {"title": "N1", "content": "methyl group preferred; bulky group decreases activity because it prevents binding to BZR" },
                              {"title": "C3", "content": "OH group eliminates first pass metabolism as the hydroxyl acts as a “handle” for conjugation." },
                              {"title": "Ring C", "content": "Hydrophobic interaction with BZR" },
                              {"title": "C4", "content": "Steric repulsion occurs with para substituent" },
                              {"title": "C2", "content": "F or Cl substitution reduces aromatic hydroxylation and improves half-life" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "When taken orally, most BZD show rapid and complete absorption from GI tract" },
                              {"title": "Distribution", "content": "-Increase lipophilicity = Increase rate of CNS distribution. -Cross BBB by passive diffusion." }, 
                              {"title": "Metabolism", "content": "-Do NOT induce metabolism of other drugs. -Liver metabolized to active compounds (except lorazepam)" },
                              {"title": "Excretion", "content": "By kidneys" },
                              {"title": "Duration of Action", "content": "[Short Acting]: 1.5-5 hours, Not converted into active intermediates. [Intermediate Acting]: 8-20 hours. [Long Acting]: 30-60 hours, Converted into active intermediates." }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa.PNG" },
                              {"title": "Mechanism of Action", "content": "-Potentiates GABA by binding to allosteric site on receptor. Increase the frequency of Cl- channel opening. -Enhancement of GABA activity slows nerve impulses throughout the body, GABA produces calming effect in the brain." },
                              {"title": "Pharmacological Action", "content": "-Sedation (decrease latency and REM). -Reduction in muscle tone. -Tolerance develops after 1-2 weeks of use. -Reduction in anxiety." }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Drowsiness, Fatigue, Amnesia, Ataxia" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "Anti-Epileptic (diazepam, lorazepam), Insomnia (temazepam, triazolam), Anti-anxiety (diazepam, lorazepam), Muscle spasms (diazepam), Anesthesia (diazepam, lorazepam, midazolam). *Duration of Action determines therapeutic use." }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "-Duration of action and elimination half life are NOT the same. -BZD increase frequency of Cl- channel opening. -GABA must be present for BZD to have effect. -Flumazenil = BZD receptor antagonist for treatment of acute overdose." }
                        ]
                  }
            ]
      },
      {
            "id": 2,
            "name": "Barbiturates",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over the compound to learn about the SAR Characteristics",
                        "imagePath" : "slide26.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 234,
                                    "x": 191,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 234,
                                    "x": 307,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 164,
                                    "x": 250,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 311,
                                    "x": 334,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 311,
                                    "x": 163,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 365,
                                    "x": 253,
                                    "size": 55,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 300,
                                    "x": 250,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Disubstitution Required for Activity",
                        "imagePath" : "slide27a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "N1", "description" : "Barbiturates can undergo enol-keto tautomerization, which gives them near neutral pkas (7.4). Less than 50% gets ionized, so good balance of solubility and CNS penetration." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Disubstitution Required for Activity",
                        "imagePath" : "slide27b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "N1", "description" : "Without any substitution at position 5, the acidic hydrogen gets deprotonated. Resonance stabilization leads to lower pka (4) and 99% ionization occurs, so unable to penetrate the CNS." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Phenobarbital to learn about the SAR Characteristics",
                        "imagePath" : "slide28a.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 218,
                                    "x": 180,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 218,
                                    "x": 302,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 162,
                                    "x": 238,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 294,
                                    "x": 162,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 294,
                                    "x": 314,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 385,
                                    "x": 262,
                                    "size": 80,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 288,
                                    "x": 238,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Hover over Thiopental to learn about the SAR Characteristics",
                        "imagePath" : "slide28b.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "N1",
                                    "y": 210,
                                    "x": 174,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "N3",
                                    "y": 210,
                                    "x": 274,
                                    "size": 40,
                                    "color": "orange",
                                    "text": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action."
                              },
                              {
                                    "name": "C2",
                                    "y": 160,
                                    "x": 222,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Changing C=O → C=S increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 270,
                                    "x": 152,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "C4 & C6",
                                    "y": 270,
                                    "x": 294,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Must contain C=O"
                              },
                              {
                                    "name": "R1 & R2",
                                    "y": 364,
                                    "x": 234,
                                    "size": 80,
                                    "color": "deeppink",
                                    "text": "bulky carbon groups increases lipophilicity and more rapid onset of action"
                              },
                              {
                                    "name": "5,5",
                                    "y": 268,
                                    "x": 223,
                                    "size": 30,
                                    "color": "goldenrod",
                                    "text": "disubstitution required for activity"
                              }
                        ],
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "N1", "description" : "N1: Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." },
                              {"color": "orange", "location": "N3", "description" : "N3: must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action " },
                              {"color": "green", "location": "C2", "description" : "C2: changing C=O → C=S increases lipophilicity and more rapid onset of action" },
                              {"color": "blue", "location": "C4 & C6", "description" : "C4 & C6: must contain C=O" },
                              {"color": "deeppink", "location": "R1 & R2", "description" : "R1 & R2: bulky carbon groups increases lipophilicity and more rapid onset of action " }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide30.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Changing C=S to C=O decreases lipophilicity and onset of action"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide31.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "5,5- disubstitution needed for activity in order for CNS penetration"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide33.PNG",
                        "question" : "Which of these 3 compounds would be a CNS active barbiturate?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "5,5- disubstitution and weak acid (N1 or N3 must be unsubstituted) are required for activity in order for CNS penetration"
                  }
            ],
            "testItems":[
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Higher doses of barbiturates bind these receptors in the cerebellum",
                        "options" : [
                              "GABAa", 
                              "GABAb", 
                              "glutamate"
                        ],
                        "answer" : "GABAa"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "The long half life of barbiturates causes this effect",
                        "options" : [
                              "hangover", 
                              "rebound"
                        ],
                        "answer" : "hangover"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "The short half life or abrupt discontinuation of barbiturates causes this effect",
                        "options" : [
                              "hangover", 
                              "rebound"
                        ],
                        "answer" : "rebound"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Higher doses of barbiturates bind [ans] receptors in the cerebellum causing the side effect of",
                        "options" : [
                              "Ataxia", 
                              "amnesia", 
                              "sedation"
                        ],
                        "answer" : "sedation"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Phenobarbital (Long Acting)", "imagePath": "phenobarbital.PNG" },
                              {"title": "Butabarbital (Intermediate Acting)", "imagePath": "butabarbital.PNG" }, 
                              {"title": "Pentobarbital (Short Acting)", "imagePath": "pentobarbital.PNG" },
                              {"title": "Secobarbital (Short Acting)", "imagePath": "secobarbital.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "" },
                              {"title": "Distribution", "content": "" }, 
                              {"title": "Metabolism", "content": "" },
                              {"title": "Excretion", "content": ""  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "moa-barbiturates.PNG" },
                              {"title": "MOA Explanation", "content": "" },
                              {"title": "Pharmacological Action", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Reason for Limited Use",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Phenobarbital (Long Acting)", "imagePath": "phenobarbital.PNG" },
                              {"title": "Butabarbital (Intermediate Acting)", "imagePath": "butabarbital.PNG" }, 
                              {"title": "Pentobarbital (Short Acting)", "imagePath": "pentobarbital.PNG" },
                              {"title": "Secobarbital (Short Acting)", "imagePath": "secobarbital.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "N1", "content": "Must be a nitrogen and unsubstitued if N3 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." },
                              {"title": "N3", "content": "Must be a nitrogen and unsubstituted if N1 is substituted. Carbon group substitution will increase lipophilicity and more rapid onset of action." }, 
                              {"title": "C2", "content": "Changing C=O → C=S increases lipophilicity and more rapid onset of action" },
                              {"title": "C4 & C6", "content": "Must contain C=O" },
                              {"title": "R1 & R2", "content": "bulky carbon groups increases lipophilicity and more rapid onset of action" },
                              {"title": "C5", "content": "Must be disubstituted alkyl groups to be active in the CNS" }
                        ]
                  },
                  {
                        "title": "Pharmokinetic",  
                        "sections" : [
                              {"title": "Absorption", "content": "IV and Oral" },
                              {"title": "Distribution", "content": "Increases lipid solubility = quicker entry into CNS. Barbiturates redistribute from brain to muscles and fat tissue." }, 
                              {"title": "Metabolism", "content": "Metabolized in the liver" },
                              {"title": "Excretion", "content": "Excreted in urine by kidney"  }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "moa-barbiturates.PNG" },
                              {"title": "MOA Explanation", "content": "Prolong GABA activity. Increase duration of Cl- channel opening. Also blocks the AMPA- receptor which is sensitive to glutamate, the excitatory transmitter. Blocking this action increases the duration of receptor response to GABA and extends the depressed condition of the cell." },
                              {"title": "Pharmacological Action", "content": "[CNS Depression]: Sedation at low doses. Hypnosis followed by anesthesia at high doses. [Respiratory Depression]: Suppress hypoxic and chemoreceptor response to C02 -> Can lead to death." }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Alcohol like symptoms: Impaired motor control (ataxia), dizziness, slower breathing and heart rate. Enzyme induction (CYP450). Potential for addiction." }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "NOT used as sedative or hypnotic. Anesthetic: Ultra short acting (thiopental). Anti-seizure: Long acting (phenobarbital)." }
                        ]
                  },
                  {
                        "title": "Reason for Limited Use",  
                        "sections" : [
                              {"title": "Notes", "content": "Physical dependence, Severe withdrawal symptoms, low toxicity threshold, tolerance develops." }
                        ]
                  }
            ]
      },
      {
            "id": 3,
            "name": "Z-Drugs",
             "learnItems":[
                  {
                        "title":"Useful Structures",  
                        "name" : "Zaleplon",
                        "imagePath" : "zaleplon-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Eszopiclone",
                        "imagePath" : "eszopiclone-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Zolpidem",
                        "imagePath" : "zolpidem-useful.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Z-Drugs" }
                        ]
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide44.PNG",
                        "question" : "Trissa is 30-year old female suffering from anxiety and insomnia. What one compound would be best to treat both her anxiety and insomnia?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Benzodiazepine (Compound 2)"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide45.PNG",
                        "question" : "Sakiya is 24-year old female suffering from anxiety and insomnia. Sakiya’s boyfriend takes one of these hypnotics for insomnia and it helps keep him asleep with no hangover effects in the morning. LM decides to take one of his pills, but in the morning she is still sleepy. Which of these compounds did she take and why is she still experiencing effects in the morning?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Zolpidem (Compound 1); women metabolize slower"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide46.PNG",
                        "question" : "Lance is 27-year old female suffering from anxiety and insomnia. Unfortunately, Lance has had abuse disorders in the past. Which of these compounds would be safest to use to treat her insomnia?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Ramelteon (Compound 3); not a scheduled drug"
                  }
            ],
            "testItems":[
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Eszopiclone binds to this receptor",
                        "options" : [
                              "barbiturate", 
                              "benzodiazepine", 
                              "dopamine"
                        ],
                        "answer" : "benzodiazepine"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Normal circadian rhythm is re-established by a drug acting at this receptor",
                        "options" : [
                              "dopamine", 
                              "serotonin", 
                              "melatonin"
                        ],
                        "answer" : "melatonin"
                  },
                  {
                        "title":"Mechanism of Action",  
                        "question" : "Eszopiclone binds to the benzodiazepine receptor and potentiates",
                        "options" : [
                              "GABA", 
                              "Glutamate", 
                              "dopamine"
                        ],
                        "answer" : "GABA"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Normal circadian rhythm is re-established at the melatonin receptor when this drug acts upon it",
                        "options" : [
                              "zolpidem", 
                              "mirtazapine", 
                              "ramelteon "
                        ],
                        "answer" : "ramelteon"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug has the longest half-life",
                        "options" : [
                              "Zolpidem", 
                              "Eszopiclone", 
                              "Ramelteon"
                        ],
                        "answer" : "Eszopiclone"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug has the longest potency",
                        "options" : [
                              "Zolpidem", 
                              "Eszopiclone", 
                              "Ramelteon"
                        ],
                        "answer" : "Zolpidem"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "This drug is used to induce sleep",
                        "options" : [
                              "zolpidem", 
                              "zaleplon", 
                              "eszopiclone"
                        ],
                        "answer" : "zolpidem"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Zolpidem is metabolized slower by ",
                        "options" : [
                              "Men", 
                              "Women"
                        ],
                        "answer" : "Women"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "John Smith is waking up regularly in the middle of the night. A good therapy for him would be",
                        "options" : [
                              "zolpidem",
                              "eszopiclone", 
                              "zaleplon"
                        ],
                        "answer" : "zaleplon"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Both the a1 and a1 benzodiazepine receptor is acted upon by ",
                        "options" : [
                              "eszopiclone", 
                              "zaleplon", 
                              "zolpidem "
                        ],
                        "answer" : "eszopiclone"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs primarily cause",
                        "options" : [
                              "sedation", 
                              "amnesia", 
                              "anxiety relief"
                        ],
                        "answer" : "sedation"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs bind primarily to this receptor",
                        "options" : [
                              "GABA", 
                              "benzodiazepine", 
                              "barbiturate "
                        ],
                        "answer" : "benzodiazepine"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z-drugs bind primarily to benzodiazepine's subunit receptor:",
                        "options" : [
                              "benzodiazepine", 
                              "alpha1", 
                              "alpha2",
                              "beta"
                        ],
                        "answer" : "alpha1"
                  },
                  {
                        "title":"Side-Effects",  
                        "question" : "Z drugs are not effective antianxiety drugs because they bind primarily to the alpha1 subunit of benzodiazepine not the subunit:",
                        "options" : [
                              "benzodiazepine", 
                              "alpha1", 
                              "alpha2",
                              "beta"
                        ],
                        "answer" : "alpha2"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Zolpidem", "imagePath": "zolpidem.PNG" },
                              {"title": "Zaleplon", "imagePath": "zaleplon.PNG" }, 
                              {"title": "Eszopiclone", "imagePath": "eszopiclone.PNG" }
                        ]
                  },
                  {
                        "title": "Zolpidem",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Zaleplon",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Eszopiclone",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "" },
                              {"title": "Key Pharmacokinetic", "content": "" }, 
                              {"title": "Action/Effect", "content": "" },
                              {"title": "Side Effects", "content": "" }
                        ]
                  }
                  
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Zolpidem", "imagePath": "zolpidem.PNG" },
                              {"title": "Zaleplon", "imagePath": "zaleplon.PNG" }, 
                              {"title": "Eszopiclone", "imagePath": "eszopiclone.PNG" }
                        ]
                  },
                  {
                        "title": "Zolpidem",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Women metabolize slower. Used to treat insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Rapidly absorbed in GI tract. Rapid onset and short elimination T1/2 (2-3 hours). Metabolism: Hepatic oxidation by CYP450." }, 
                              {"title": "Action/Effect", "content": "Selective for GABA-A alpha-1 subunit. Sedative." },
                              {"title": "Side Effects", "content": "Nightmares, agitation, headache, GI upset, dizziness, drowsiness." }
                        ]
                  },
                  {
                        "title": "Zaleplon",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Used to treat insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Fewer residual effect on psychomotor and cognitive functions. Rapid elimination and T1/2 of 1 hour = Good to tak in the middle of night. Metabolism: CYP450." }, 
                              {"title": "Action/Effect", "content": "Selective for GABA-A alpha-1 subunit. Sedative." },
                              {"title": "Side Effects", "content": "Dizziness, Drowsiness, Lack of coordination." }
                        ]
                  },
                  {
                        "title": "Eszopiclone",  
                        "sections" : [
                              {"title": "Key Characteristics", "content": "Longest T1/2. Used for chronic insomnia." },
                              {"title": "Key Pharmacokinetic", "content": "Elimination half life ~6 hours. Metabolism: oxidation and demethylation via CYP450. Rapidly absorbed." }, 
                              {"title": "Action/Effect", "content": "Acts at several GABA-A subunits, including alpha-1 and alpha-2 subunit. Sedative and Anxiolytic." },
                              {"title": "Side Effects", "content": "Anxiety, dry mount, headache, peripheral edema, somnolence, unpleasant taste." }
                        ]
                  }
                  
            ]
      },
      {
            "id": 4,
            "name": "Anticonvulsants",
            "learnItems":[
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Phenobarbital (barbiturate) to learn about the SAR Trends",
                        "imagePath" : "phenobarbital-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Phenobarbital Ureide",
                                    "y": 214,
                                    "x": 300,
                                    "size": 65,
                                    "color": "green",
                                    "text": "Phenobarbital's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Ethosuximide (succinimide) to learn about the SAR Trends",
                        "imagePath" : "ethosuximide-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Ethosuximide Ureide",
                                    "y": 300,
                                    "x": 250,
                                    "size": 50,
                                    "color": "green",
                                    "text": "Ethosuximide's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Phenytoin (hydantion) to learn about the SAR Trends",
                        "imagePath" : "phenytoin-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Phenytoin Ureide",
                                    "y": 286,
                                    "x": 270,
                                    "size": 50,
                                    "color": "green",
                                    "text": "Phenytoin's Ureide Common Scaffold"
                              }
                        ]
                  },
                  {
                        "title":"SAR Trends",  
                        "name" : "Hover over Fosphenytoin (hydantion) to learn about the SAR Trends",
                        "imagePath" : "fosphenytoin-sar.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "Fosphenytoin Ureide",
                                    "y": 250,
                                    "x": 255,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Fosphenytoin's Ureide Common Scaffold"
                              }
                        ]
                  },
                   {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide63.PNG",
                        "question" : "Henry is 45-year old male who has recently been suffering from  what is believed to be absence seizures. Which compound should he be prescribed?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Ethosuximide (Compound 2); best used for absence seizures"
                  },
                   {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide64.PNG",
                        "question" : "Amir is 48-year old male who has recently been suffering from what is believed to be absence seizures. Unfortunately, ethosuximide was not effective, and it is decided that Amir needs a medication for partial seizures instead. Amir also is taking several other medications. Which compound should he take?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : ": Lamotrigine (Compound 3); not metabolized by CYP and does not induce CYP, which could interfere with other medications"
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs primarily reduce this activity",
                        "options" : [
                              "excitatory", 
                              "inhibitory "
                        ],
                        "answer" : "excitatory"
                  },
                  {
                        "title":"",  
                        "question" : "Consciousness is impaired for 30 seconds - 2 minutes by this seizure type: ",
                        "options" : [
                              "partial", 
                              "complex partial",
                              "absence "
                        ],
                        "answer" : "complex partial"
                  },
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs targeting sodium channels block",
                        "options" : [
                              "Sodium efflux",
                              "normal action potentials",
                              "epileptiform discharges"
                        ],
                        "answer" : "epileptiform discharges"
                  },
                  {
                        "title":"",  
                        "question" : "Antiepileptic drugs primarily enhance this activity",
                        "options" : [
                              "excitatory", 
                              "inhibitory "
                        ],
                        "answer" : "inhibitory"
                  },
                  {
                        "title":"",  
                        "question" : "Felbamate is an antiepileptic that blocks these receptors",
                        "options" : [
                              "AMPA", 
                              "dopamine",
                              "GABA",
                              "NMDA"
                        ],
                        "answer" : "GABA"
                  },
                  {
                        "title":"",  
                        "question" : "Reducing seizures and weight is possible with this anticonvulsant drug",
                        "options" : [
                              "topiramate", 
                              "valproic acid",
                              "gabapentin"
                        ],
                        "answer" : "topiramate"
                  },
                  {
                        "title":"",  
                        "question" : "Ethosuximide acts by inhibiting the activity of these channels",
                        "options" : [
                              "Calcium",
                              "Sodium",
                              "Chloride",
                              "Potassium"
                        ],
                        "answer" : "Calcium"
                  },
                  {
                        "title":"",  
                        "question" : "Ethosuximide is only used for this type of seizure",
                        "options" : [
                              "complex",
                              "partial",
                              "absence "
                        ],
                        "answer" : "absence"
                  },
                  {
                        "title":"",  
                        "question" : "This drug induces its own metabolism",
                        "options" : [
                              "Phenytoin", 
                              "Carbamazepine",
                              "Gabapentin"
                        ],
                        "answer" : "Carbamazepine"
                  },
                  {
                        "title":"",  
                        "question" : "Steven's Johnson syndrome is a rare but serious side effect of",
                        "options" : [
                              "Levetiracetam", 
                              "Lamotrigine",
                              "Carbamazepine"
                        ],
                        "answer" : "Lamotrigine"
                  },
                  {
                        "title":"",  
                        "question" : "Dizziness and somnolence is the most common side effect of",
                        "options" : [
                              "Phenytoin & Gabapentin", 
                              "Pregabalin & Phenobarbital",
                              "Pregabalin & Gabapentin",
                              "Phenobarbital & Gabapentin"
                        ],
                        "answer" : "Pregabalin & Gabapentin"
                  },
                  {
                        "title":"",  
                        "question" : "This binds to a synaptic vesicle protein and reduces presynaptic neurotransmitter release mediated by Ca2+",
                        "options" : [
                              "Levetiracetam", 
                              "Lamotrigine",
                              "topiramate"
                        ],
                        "answer" : "Levetiracetam"
                  },
                  {
                        "title":"",  
                        "question" : "Carbamazepine can be administered most safely without interaction with",
                        "options" : [
                              "lorazepam", 
                              "phenytoin",
                              "diazepam"
                        ],
                        "answer" : "diazepam"
                  },
                  {
                        "title":"",  
                        "question" : "This is an irreversible inhibitor of GABA transaminase",
                        "options" : [
                              "Gabapentin", 
                              "Pregabalin",
                              "Valproic acid",
                              "Vigabatrin "
                        ],
                        "answer" : "Vigabatrin"
                  }

            ], 
            "reviewItems":[
                  {
                        "title": "Epilepsy",  
                        "sections" : [
                              {"title": "Pathophysiology of a seizure", "content": "" },
                              {"title": "Common toxicities of many antiepileptic drugs", "content": "" }, 
                              {"title": "Notes", "content": "" }
                        ]
                  },
                  {
                        "title": "Molecular Targets for Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Decrease Excitatory Activity", "content": "" },
                              {"title": "Increase Inhibitory Activity", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Ca+ Channel) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Na+ Channel) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: Synaptic Vesicle Protein) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: PAM @ GABA-A) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  },
                  {
                        "title": "(Target/MOA: GABA Metabolism) Treatment Drugs",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "" },
                              {"title": "Neurotransmitter", "content": "" },
                              {"title": "Drugs", "content": "" }
                        ]
                  }
            ],
             "exampleReview":[
                  {
                        "title": "Epilepsy",  
                        "sections" : [
                              {"title": "Pathophysiology of a seizure", "content": "Finite episodes of brain dysfunction resulting from abnormal repetitive discharge of cerebral neurons." },
                              {"title": "Common toxicities of many antiepileptic drugs", "content": "Sedation, Rashes, Teratogenicity, Cerebellar: Ataxia & Nystagmus, CYP450 Interactions." }, 
                              {"title": "Notes", "content": "Anti-epileptics do not block ALL action potentials - blocking all would cause death." }
                        ]
                  },
                  {
                        "title": "Molecular Targets for Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Decrease Excitatory Activity", "content": "*Works at Glutamatergic synapse. 1. Block NA+ Channels. 2. Block Ca+ Channels. 3. Activate K+ Channels. 4. Block NMDA-Receptor. 5. Block NMDA-Receptor. 6. Bind to Synaptic Vesicle Proteins." },
                              {"title": "Increase Inhibitory Activity", "content": "*Works at GABAergic synapse. 1. Block GABA Transporter (More GABA in synapse). 2. Block GABA Transaminase (Block metabolism of GABA). 3. Increase potency of GABA @ GABA-A Receptor." }
                        ]
                  },
                  {
                        "title": "(Ca+ Channel) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Decrease Ca+ Channel Activity" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Phenobarbital, Ethosuximide, Valproic Aid, Gabapentin, Pregabalin" }
                        ]
                  },
                  {
                        "title": "(Na+ Channel) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Decrease Na+ Channel Activity" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Phenytoin, Carbamazepine, Valproic Acid, Lamotrigine, Topiramate" }
                        ]
                  },
                  {
                        "title": "(Synaptic Vesicle Protein) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Binds to synaptic vesicle protein to reduce presynaptic NT release" },
                              {"title": "Neurotransmitter", "content": "Glutamate (Decrease excitatory activity)" },
                              {"title": "Drugs", "content": "Levetiracetam" }
                        ]
                  },
                  {
                        "title": "(PAM @ GABA-A) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "PAM @ GABA-A" },
                              {"title": "Neurotransmitter", "content": "GABA (increase inhibitory activity)" },
                              {"title": "Drugs", "content": "Phenobarbital, Diazepam, Lorazepam" }
                        ]
                  },
                  {
                        "title": "(GABA Metabolism) Epilepsy Treatment",  
                        "sections" : [
                              {"title": "Target/MOA", "content": "Inhibition of GABA metabolism" },
                              {"title": "Neurotransmitter", "content": "GABA (increase inhibitory activity)" },
                              {"title": "Drugs", "content": "Valproic Acid" }
                        ]
                  }
            ]
      },
      {
            "id": 5,
            "name": "SRIs",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Phenoxyphenylalkyl Amines",
                        "imagePath" : "slide3.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 8.7−9.8" },
                              {"color": "deeppink", "location": "Electron-withdrawing group", "description" : "Electron-withdrawing group: para or meta substitution enhances binding affinity for SERT; while Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" },
                              {"color": "red", "location": "Phenoxy", "description" : "Phenoxy: distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)." }
                        ]
                  },
                  {
                        "title":"Phenoxyphenylalkyl Amines Example",  
                        "name" : "Fluoxetine",
                        "imagePath" : "slide-5a.PNG",
                        "colorLocationAssociations" : [
                               {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 8.7−9.8" },
                              {"color": "deeppink", "location": "Electron-withdrawing group", "description" : "Electron-withdrawing group: para or meta substitution enhances binding affinity for SERT; while Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" },
                              {"color": "red", "location": "Phenoxy", "description" : "Phenoxy: distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)." }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Phenylalkyl Amines",
                        "imagePath" : "slide4.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 9.5" },
                              {"color": "deeppink", "location": "Chlorine", "description" : "Chlorine: enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title":"Phenylalkyl Amines Example",  
                        "name" : "Sertraline",
                        "imagePath" : "slide-5b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "green", "location": "Basic Nitrogen", "description" : "Basic nitrogen: protonated at physiological pH; pKa 9.5" },
                              {"color": "deeppink", "location": "Chlorine", "description" : "Chlorine: enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide7.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "The presence of an EWG (CF3) increases SERT activity of phenoxyphenylalkyl amines"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide8.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "The presence of the phenoxy (O directly attached to phenyl ring) distinguishes SRIs from diphenhydramine"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide9.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "The S isomer of fluoxetine is 100x more selective for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide10.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Ortho EWG substitution results in NRI and decreases SERT affinity"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide12.PNG",
                        "question" : "Which of these 3 antidepressants has major side effects as GI upset and sexual dysfunction?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Paroxetine is an SRI, which commonly shows these adverse events"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide13.PNG",
                        "question" : "Which of these 3 antidepressants is most selective for SERT?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Sertraline is an SRI, which is selective for SERT. Compound 1 is an NRI and compound 2 is a secondary amine TCA, which is more selective for NET."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide15.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compounds (1, 3)",
                        "options" : [ 
                              "Active, Active",
                              "Active, Inactive",
                              "Inactive, Active",
                              "Inactive, Inactive"
                        ],
                        "answer" : "Inactive, Active",
                        "explanation" : ""
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Escitalopram, fluoxetine, sertraline, and citalopram are examples of:",
                        "options" : [
                              "Tricyclic antidepressants",
                              "Atypical antidepressants",
                              "Norepinephrine Reuptake Inhibitors",
                              "Serotonin Reuptake Inhibitors"
                        ],
                        "answer" : "Serotonin Reuptake Inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "___________ are the most widely prescribed antidepressants",
                        "options" : [
                              "TCAs",
                              "SRIs",
                              "Lithium",
                              "SNRIs"
                        ],
                        "answer" : "SRIs"
                  },
                  {
                        "title":"",  
                        "question" : "__________ inhibits CYPs more significantly than other _______",
                        "options" : [
                              "(Escitalopram, TCAs)",
                              "(Sertraline, Atypical Antidepressants)",
                              "(Fluoxetine, SRIs)",
                              "(Citalopram, NRIs)"
                        ],
                        "answer" : "(Fluoxetine, SRIs)"
                  },
                  {
                        "title":"",  
                        "question" : "The most common adverse effects of SRIs GI and ________________",
                        "options" : [
                              "sexual side effects",
                              "orthostatic hypotension",
                              "constipation",
                              "drowsiness"
                        ],
                        "answer" : "sexual side effects"
                  },
                  {
                        "title":"",  
                        "question" : "SRIs have common drug interactions with _______ and can cause elevated levels of __________",
                        "options" : [
                              "(Acetylcholinesterase inhibitors, Acetylcholine)",
                              "(Anticonvulsants, Norepinephrine)",
                              "(Antibiotics, Dopamine)",
                              "(MAOIs, Serotonin)"
                        ],
                        "answer" : "(MAOIs, Serotonin)"
                  },
                  {
                        "title":"",  
                        "question" : "_________ can be recognized with side effects such as increased heart rate and diarrhea",
                        "options" : [
                              "Orthostatic Hypotension,",
                              "Antihistaminic Effects,",
                              "Serotonin Syndrome",
                              "Antimuscarinic Effects"
                        ],
                        "answer" : "Serotonin Syndrome"
                  },
                  {
                        "title":"",  
                        "question" : "SRIs are ________ tolerated than TCA",
                        "options" : [
                              "more",
                              "less",
                              "equally"
                        ],
                        "answer" : "more"
                  },
                  {
                        "title":"",  
                        "question" : "Abrupt withdrawal of SRIs can cause:",
                        "options" : [
                              "physical dependence",
                              "rebound effect",
                              "hangover",
                              "medullary depression"
                        ],
                        "answer" : "rebound effect"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Paroxetine (Pheno)", "imagePath": "paroxetine.PNG" },
                              {"title": "Escitalopram (Pheno)", "imagePath": "escitalopram.PNG" }, 
                              {"title": "Fluoxetine (Pheno)", "imagePath": "fluoxetine.PNG" },
                              {"title": "Sertraline (Pheny)", "imagePath": "sertraline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenoxyphenylalkyl Amines",  
                        "sections" : [
                              {"title": "Phenoxyphenylalkyl Amines", "imagePath": "sarCharacteristics-pheno.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenylalkyl Amine",  
                        "sections" : [
                              {"title": "Phenylalkyl Amine", "imagePath": "sarCharacteristics-pheny.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "mechanismAction.PNG" },
                              {"title": "Explanation", "content": "" },
                              {"title": "Acute SRI Use", "content": "" },
                              {"title": "Chronic SRI Use", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
             "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Paroxetine (Pheno)", "imagePath": "paroxetine.PNG" },
                              {"title": "Escitalopram (Pheno)", "imagePath": "escitalopram.PNG" }, 
                              {"title": "Fluoxetine (Pheno)", "imagePath": "fluoxetine.PNG" },
                              {"title": "Sertraline (Pheny)", "imagePath": "sertraline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenoxyphenylalkyl Amines",  
                        "sections" : [
                              {"title": "Phenoxyphenylalkyl Amines", "imagePath": "sarCharacteristics-pheno.PNG" },
                              {"title": "Basic nitrogen: ", "content": "protonated at physiological pH; pKa 8.7−9.8" },
                              {"title": "Electron-withdrawing group: ", "content": "para or meta substitution enhances binding affinity for SERT. -Ortho substitution (except CF3) enhances binding affinity for NET and results in NRI" }, 
                              {"title": "Phenoxy:", "content": "distinguishes antidepressant and antihistamine activity (derived from diphenhydramine)" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics - Phenylalkyl Amine",  
                        "sections" : [
                              {"title": "Phenylalkyl Amine", "imagePath": "sarCharacteristics-pheny.PNG" },
                              {"title": "Basic Nitrogen", "content": "Protonated at physiological pH; pKa 9.5" },
                              {"title": "Chlorine", "content": "enhances SERT selectivity" }
                        ]
                  },
                  {
                        "title": "Action",  
                        "sections" : [
                              {"title": "Mechanism of Action", "imagePath": "mechanismAction.PNG" },
                              {"title": "Explanation", "content": "Blocks Serotonin Transporter (SERT) on pre-synaptic neuron resulting in increased serotonin in the synapse which is available to bind to post synaptic serotonin receptors." },
                              {"title": "Acute SRI Use", "content": "1. Drug blocks 5-HT re-update (SERT) 2. Auto receptor (5-HT1A) activity decreases 3. 5-HT release decreases" },
                              {"title": "Chronic SRI Use", "content": "1. Auto receptor (5-HT1A) function is lost 2. 5-HT release returns to normal 3. Now serotonin in synapse is greatly increased" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "Nausea & GI symptoms, Sexual effects (decreased libido & sexual dysfunction), Mild restlessness, Mild headaches, Mild Insomnia" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "Depression, OCD, panic disorder, anxiety" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "SRIs compete with metabolism of other drugs, Never use in combo with MAOIs (MAOIs inhibit breakdown of SRIs and could lead to overdose of serotonin in the brain)" }
                        ]
                  }
            ]
      },
      {
            "id": 6,
            "name": "SNRIs",
            "learnItems":[
                  {
                        "title":"Helpful Strucures to Know",  
                        "name" : "Duloxetine",
                        "imagePath" : "slide-23a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "None", "description" : "Serotonin and Norepinephrine Reuptake Inhibitors do not have any Structure Activity Requirements but these are some helpful structures to be familiar with." }
                        ]
                  },
                  {
                        "title":"Helpful Strucures to Know",  
                        "name" : "Venlafaxine",
                        "imagePath" : "slide-23b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "None", "description" : "Serotonin and Norepinephrine Reuptake Inhibitors do not have any Structure Activity Requirements but these are some helpful structures to be familiar with." }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide25.PNG",
                        "question" : "Which of these 3 antidepressants is active at both SERT and NET?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Duloxetine is an SNRI, which is active at SERT and NET. Compound 1 is SRI and Compound 3 is bupropion, which weakly blocks DAT and NET"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide26.PNG",
                        "question" : "Which of these 3 antidepressants is considered activating and may raise blood pressure?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : " Venlafaxine is an SNRI, which is known to be activating"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide28.PNG",
                        "question" : "Alfred Smith is 80-year old male suffering from depression. He is currently taking paroxetine, but it is not helping. What one compound would you recommend he try next?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 1 is an SRI, which he was currently taking and not helping. Compound 2 is a tertiary amine TCA, which acts as a SNRI and would be helpful, but leads to adverse effects such as sedation and hypotension so not recommended in elderly. Compound 3 (venlafaxine) is best choice as it is SNRI, with few adverse effects."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Venlafaxine and duloxetine are examples of: ",
                        "options" : [
                              "Tricyclic Antidepressants",
                              "Atypical Antidepressants",
                              "Serotonin-Norepinephrine Reuptake Inhibitors",
                              "Selective Serotonin Reuptake Inhibitors"
                        ],
                        "answer" : "Serotonin-Norepinephrine Reuptake Inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "SNRI’s have _________ effects such as agitation",
                        "options" : [
                              "seratonergic",
                              "noradrenergic",
                              "histaminergic",
                              "cholinergic"
                        ],
                        "answer" : "noradrenergic"
                  },
                  {
                        "title":"",  
                        "question" : "(venlafaxine/duloxetine) is more potent than (venlafaxine/duloxetine)",
                        "options" : [
                              "(venlafaxine, duloxetine)",
                              "(duloxetine, venlafaxine)"
                        ],
                        "answer" : "(venlafaxine, duloxetine)"
                  },
                  {
                        "title":"",  
                        "question" : "SNRI’s are similar to TCA potency, have (less/more) side effects, and (faster/slower) than SRI alone",
                        "options" : [
                              "(less, faster)",
                              "(more, slower)",
                              "(more, faster)",
                              "(less, slower)"
                        ],
                        "answer" : "(less, faster)"
                  },
                  {
                        "title":"",  
                        "question" : "_________ has an active metabolite",
                        "options" : [
                              "Duloxetine",
                              "Sibutramine",
                              "Venlafaxine",
                              "Milnacipran"
                        ],
                        "answer" : "Venlafaxine"
                  },
                  {
                        "title":"",  
                        "question" : "BONUS: Venlafaxine's active metabolite's name is:",
                        "options" : [
                              "Ansofaxine",
                              "Duloxetine",
                              "Atomoxetine",
                              "Desvenlafaxine"
                        ],
                        "answer" : "Desvenlafaxine"
                  }
            ], 
            "reviewItems":[]
      },
      {
            "id": 7,
            "name": "Tricyclic-Antidepressants",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Tertiary Amines",
                        "imagePath" : "slide34.PNG",
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Linker of 3 carbons", "description" : "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"color": "deeppink", "location": "R→ CH3", "description" : "R→ CH3, tertiary amine imparts selectivity for SERT" },
                              {"color": "blue", "location": "R’→ Cl or CN (EWG)", "description" : "R’→ Cl or CN (EWG) enhances binding affinity for SERT" },
                              {"color": "green", "location": "Y→ can be C or N", "description" : "Y→ can be C or N" },
                              {"color": "purple", "location": "Conformationally rigid [6.7.6]-fused ring system", "description" : "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title":"Tertiary Amines Example Compound",  
                        "name" : "Clomipramine",
                        "imagePath" : "slide-36a.PNG",
                        "colorLocationAssociations" : []
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Secondary Amines",
                        "imagePath" : "slide35.PNG",
                        "colorLocationAssociations" : [
                              {"color": "red", "location": "Linker of 3 carbons", "description" : "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"color": "deeppink", "location": "R→ CH3", "description" : "R→ H, secondary amine imparts selectivity for NET" },
                              {"color": "blue", "location": "R’→ Cl or CN (EWG)", "description" : "R’→ no substitution decreases SERT preference" },
                              {"color": "green", "location": "Y→ can be C or N", "description" : "Y→ can be C or N" },
                              {"color": "purple", "location": "Conformationally rigid [6.7.6]-fused ring system", "description" : "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title":"Secondary Amines Example Compound",  
                        "name" : "Nortriptyline",
                        "imagePath" : "slide-36b.PNG",
                        "colorLocationAssociations" : []
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide38.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Tertiary→ Secondary amine decreases binding affinity for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide39.PNG",
                        "question" : "Would the following change to the compound increase, decrease, or have no effect upon activity at SERT?",
                        "options" : [
                              "Increase", 
                              "Decrease", 
                              "No Effect"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Presence of EWG (Cl) enhances binding affinity for SERT"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide41.PNG",
                        "question" : "Which of these 3 antidepressants is active at both SERT and NET?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2, amitriptyline is a tertiary TCA, which is active at SERT and NET. Compound 1 is SRI and Compound 3 is a secondary TCA, only active at NET"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide42.PNG",
                        "question" : "Which of these 3 antidepressants causes significant dry mouth, constipation, and sedation?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1, clomipramine is a tertiary TCA, which is can bind to muscarinic and histamine receptors resulting in off target adverse effects. Compound 2 is a SRI and does not cause these adverse effects. Compound 3 is a mirtazepine and while it can cause sedation, it does not display anticholinergic effects such as dry mouth and constipation."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide44.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound products. Would amitriptyline be an ideal antidepressant for the elderly?",
                        "options" : [ 
                              "Active, Active, Yes",
                              "Active, Inactive, No", 
                              "Inactive, Inactive, No",
                              "Inactive, Active, Yes"
                        ],
                        "answer" : "Active, Inactive, No",
                        "explanation" : "Aamitriptyline causes anticholinergic effects, therefore it is not an ideal antidepressant for the elderly."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide45.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound products",
                        "options" : [ 
                              "Active, Active",
                              "Active, Inactive", 
                              "Inactive, Inactive",
                              "Inactive, Active"
                        ],
                        "answer" : "Active, Inactive",
                        "explanation" : "No explanation for this item."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Predict Metabolite Activity",
                        "imagePath" : "slide46.PNG",
                        "question" : "Predict whether the metabolites will be active or inactive for the compound product. Is nortriptyline considered an SNRI or NRI?",
                        "options" : [ 
                              "Active, NRI",
                              "Active, SNRI", 
                              "Inactive, NRI",
                              "Inactive, SNRI"
                        ],
                        "answer" : "Inactive, NRI",
                        "explanation" : "Nortriptyline is a secondary TCA so it is more selective for NET."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Tertiary TCAs have slightly greater selectivity for blockade of (Norepinephrine/Serotonin) reuptake over (Norepinephrine/Serotonin) reuptake",
                        "options" : [
                              "(Norepinephrine, Serotonin)",
                              "(Serotonin, Norepinephrine)"
                        ],
                        "answer" : "(Serotonin, Norepinephrine)"
                  },
                  {
                        "title":"",  
                        "question" : "Secondary TCA’s, such as (Nortriptyline/Amitriptyline) have greater selectivity for blockade of (Norepinephrine/Serotonin)",
                        "options" : [
                              "(Nortriptyline, Norepinephrine)",
                              "(Nortriptyline, Serotonin)",
                              "(Amitriptyline, Norepinephrine)",
                              "(Amitriptyline, Serotonin)"
                        ],
                        "answer" : "(Nortriptyline, Norepinephrine)"
                  },
                  {
                        "title":"",  
                        "question" : "TCA adverse effects include _____________ effects such as dry eyes and mouth",
                        "options" : [
                              "adrenergic",
                              "antihistaminic",
                              "anticholinergic",
                              "antimuscarinic"
                        ],
                        "answer" : "antimuscarinic"
                  },
                  {
                        "title":"",  
                        "question" : "Onset of action for TCA’s takes 2-3:",
                        "options" : [
                              "months",
                              "weeks",
                              "days",
                              "minutes"
                        ],
                        "answer" : "weeks"
                  },
                  {
                        "title":"",  
                        "question" : "Side effects include sexual dysfunction, constipation, and: ",
                        "options" : [
                              "prominent GI effects",
                              "sedation",
                              "migraines",
                              "blood disorders"
                        ],
                        "answer" : "sedation"
                  }
            ], 
            "reviewItems":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Amitriptyline (Tertiary)", "imagePath": "review-Amitriptyline.PNG" },
                              {"title": "Nortriptyline (Secondary)", "imagePath": "review-Nortriptyline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Example Compound", "imagePath": "review-sar.PNG" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" },
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" }, 
                              {"title": "", "content": "" },  
                              {"title": "", "content": "" }
                        ]
                  },
                  {
                        "title": "Mechanism of Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa-TCAs.PNG" },
                              {"title": "Explanation", "content": "" }
                        ]
                  },
                  {
                        "title": "Side-Effects",  
                        "sections" : [
                              {"title": "Side-Effects", "content": "" }
                        ]
                  },
                  {
                        "title": "Uses",  
                        "sections" : [
                              {"title": "Uses", "content": "" }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "" }
                        ]
                  }
            ],
            "exampleReview":[
                  {
                        "title": "Drugs",  
                        "sections" : [
                              {"title": "Amitriptyline (Tertiary)", "imagePath": "review-Amitriptyline.PNG" },
                              {"title": "Nortriptyline (Secondary)", "imagePath": "review-Nortriptyline.PNG" }
                        ]
                  },
                  {
                        "title": "SAR Characteristics",  
                        "sections" : [
                              {"title": "Example Compound", "imagePath": "review-sar.PNG" },
                              {"title": "Linker of 3 carbons", "content": "Linker of 3 carbons between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated." },
                              {"title": "R→ CH3, tertiary amine", "content": "R→ CH3, tertiary amine imparts selectivity for SERT" },
                              {"title": "R→ H, secondary amine", "content": "R→ H, secondary amine imparts selectivity for NET" }, 
                              {"title": "R’→ Cl or CN (EWG)", "content": "R’→ Cl or CN (EWG) enhances binding affinity for SERT" }, 
                              {"title": "R’→ no substitution", "content": "R’→ no substitution decreases SERT preference" }, 
                              {"title": "Y→ can be C or N", "content": "Y→ can be C or N" },  
                              {"title": "Conformationally rigid [6.7.6]-fused ring system", "content": "Conformationally rigid [6.7.6]-fused ring system - 7 membered ring in the middle is not coplanar; results in twisted shape" }
                        ]
                  },
                  {
                        "title": "Mechanism of Action",  
                        "sections" : [
                              {"title": "MOA", "imagePath": "moa-TCAs.PNG" },
                              {"title": "Explanation", "content": "Block SERT & NET to inhibit seratonin and norepinephrine reuptake. Block muscarinic, Histamine H1, and Alpha adrenergic receptors" }
                        ]
                  },
                  {
                        "title": "Side-Effects",
                        "sections" : [
                              {"title": "Side-Effects", "content": "[Amitriptyline]: Sedation, Hypotension, Anti-Muscarinic, Weight Gain. [Nortiptyline]: No major side effects." }
                        ]
                  },
                  {
                        "title": "Notes",  
                        "sections" : [
                              {"title": "Notes", "content": "[Amitriptyline]: Can cause extreme CNS depression leading to death if OD. [Nortiptyline]: Selectively blocks NET with much more affinity than SERT." }
                        ]
                  }
            ]
      },
      {
            "id": 8,
            "name": "Atypical-Antidepressants",
            "learnItems":[
                  {
                        "title":"Useful Structures",  
                        "name" : "Trazodone",
                        "imagePath" : "slide-53a.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Mirtazepine",
                        "imagePath" : "slide-53b.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Useful Structures",  
                        "name" : "Bupropion",
                        "imagePath" : "slide-53c.PNG",
                        "colorLocationAssociations" : [
                              {"color": "black", "location": "none", "description" : "Circled parts of each structure are helpful to associate with the compounds. There are no SAR Requirements for Atypical Antidepressants" }
                        ]
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide55.PNG",
                        "question" : "Which of these 3 antidepressants can also be used for smoking cessation?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Bupropion"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide56.PNG",
                        "question" : "Which of these 3 antidepressants causes sedation by blocking histamine receptors?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Mirtazepine"
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide57.PNG",
                        "question" : "Which of these 3 antidepressants can result in a hepatotoxic metabolite?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Metabolism of Trazodone"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide59.PNG",
                        "question" : "Mary Sue is 25-year old male suffering from depression. She complains of feeling tired and gaining weight with her last course of antidepressants. Which compound would you recommend her to try?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 1 (trazodone) can cause sedation. Compound 2 (amitriptyline) can cause weight gain. Compound 3 (bupropion) would be a good alternative for this patient to prevent unwanted adverse effects."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Significant side effect of both trazodone and mirtazepine is: ",
                        "options" : [
                              "orthostatic hypotension",
                              "sedation",
                              "constipation",
                              "sexual effects"
                        ],
                        "answer" : "sedation"
                  },
                  {
                        "title":"",  
                        "question" : "Trazodone works by blocking the ______ serotonin receptor and being an agonist at the _______ serotonin receptor",
                        "options" : [
                              "(5HT_1A, 5HT_2A)",
                              "(5HT_1D, 5HT_2B)",
                              "(5HT_2A, 5HT_1A)",
                              "(5HT_2B, 5HT_1D)"
                        ],
                        "answer" : "(5HT_2A, 5HT_1A)"
                  },
                  {
                        "title":"",  
                        "question" : "Mirtazapine blocks a serotonin receptor and a ________ receptor",
                        "options" : [
                              "adrenergic",
                              "dopamine",
                              "histamine",
                              "muscarinic"
                        ],
                        "answer" : "histamine"
                  },
                  {
                        "title":"",  
                        "question" : "Buproprion has a potential for ___________ at high doses",
                        "options" : [
                              "seizures",
                              "dyskinesia",
                              "memory loss",
                              "respiratory depression"
                        ],
                        "answer" : "seizures"
                  },
                  {
                        "title":"",  
                        "question" : "__________ can cause increase appetite and weight gain while ___________ can have the opposite effect",
                        "options" : [
                              "(Mirtazapine, Buproprion)",
                              "(Buproprion, Mirtazapine)",
                              "(Trazodone, Buproprion)",
                              "(Buproprion, Trazodone)"
                              
                        ],
                        "answer" : "(Trazodone, Buproprion)"
                  },
                  {
                        "title":"",  
                        "question" : "______________ can be used a sleep aid independent of its antidepressant activity",
                        "options" : [
                              "Fluoxetine",
                              "Mirtazapine",
                              "Buproprion",
                              "Trazadone"
                        ],
                        "answer" : "Trazadone"
                  }
            ],
             "reviewItems":[
                  {
                        "title": "Atypical Antidepressants (Trazodone)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "trazodone.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Mirtazapine)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "mirtazapine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Bupropion)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "bupropion.PNG", "content": "None"},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "SNRIs & SRIs (Venlafaxine)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "venlafaxine.PNG", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "SRIs (Escitalopram, Fluoxetine, Sertraline)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "sri-sar.PNG", "content": ""},
                              {"title": "Phenoxyphenylalkyl SAR", "content": ""},
                              {"title": "Phenylalkyl SAR", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "Tricyclic Antidepressants (Amitriptyline & Nortriptyline)",  
                        "sections" : [
                              {"title": "MOA", "content": "" },
                              {"title": "SAR", "imagePath": "triptyline.PNG", "content": ""},
                              {"title": "SAR Explained", "content": ""},
                              {"title": "Side Effects", "content": ""}
                        ]
                  },
                  {
                        "title": "THEORIES OF DEPRESSION",  
                        "sections" : [
                              {"title": "Monoamine Theory", "content": ""},
                              {"title": "Neurotrophic Theory", "content": ""}
                        ]
                  },
                  {
                        "title": "LOW NERUOTRANSMITTER LEVELS",  
                        "sections" : [
                              {"title": "Low serotonin", "content": ""},
                              {"title": "Low norepinephrine", "content": ""},
                              {"title": "Low dopamine", "content": ""}
                        ]
                  },
                  {
                        "title": "ACTIVATION OF RECEPTORS",  
                        "sections" : [
                              {"title": "5-HT", "content": ""},
                              {"title": "Adrenergic", "content": ""},
                              {"title": "Antihistamine H1", "content": ""},
                              {"title": "Alpha1-Adrenergic", "content": ""}
                        ]
                  }

            ],                     
            "exampleReview":[
                  {
                        "title": "Atypical Antidepressants (Trazodone)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SERT and alpha1-adrenergic receptor. Agonist at 5-HT1A on post-synaptic neuron." },
                              {"title": "SAR", "imagePath": "trazodone.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Sedation. [Minor]: GI, Weight Gain."}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Mirtazapine)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks H1 histamine receptor, 5HT2 receptor and alpha2-adrendergic receptor. Agonist at 5HT1A on post synaptic neuron." },
                              {"title": "SAR", "imagePath": "mirtazapine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Sedation. [Minor]: Weight Gain"}
                        ]
                  },
                  {
                        "title": "Atypical Antidepressants (Bupropion)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks DAT and NET resulting in increased dopamine and NE in extracellular space - dopamine acts on reward pathway to improve mood." },
                              {"title": "SAR", "imagePath": "bupropion.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: Insomnia, Agitation. [Minor]: Nausea, Dry Mouth"}
                        ]
                  },
                  {
                        "title": "SNRIs & SRIs (Venlafaxine)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SERT and NET resulting in increased levels of serotinin and norepinephrine in the synapse." },
                              {"title": "SAR", "imagePath": "venlafaxine.PNG", "content": "None"},
                              {"title": "Side Effects", "content": "[Major]: GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "SRIs (Escitalopram, Fluoxetine, Sertraline)",  
                        "sections" : [
                              {"title": "MOA", "content": "Selectively blocks SERT on the pre-synaptic neuron resulting in increased levels of serotonin in the synapse and increased activation of 5-HT1A receptors on post-synaptic neuron." },
                              {"title": "SAR", "imagePath": "sri-sar.PNG", "content": ""},
                              {"title": "Phenoxyphenylalkyl SAR", "content": "[Basic nitrogen]: protonated at physiological pH; pKa 8.7−9.8. [Electron-withdrawing group]: para or meta substitution enhances binding affinity for SERT. [Phenoxy]: distinguishes antidepressant and antihistamine activity derived from diphenhydramine)"},
                              {"title": "Phenylalkyl SAR", "content": "[Basic nitrogen]: protonated at physiological pH; pKa 9.5. [Chlorine]: enhances SERT selectivity."},
                              {"title": "Side Effects", "content": "[Major]: GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "Tricyclic Antidepressants (Amitriptyline & Nortriptyline)",  
                        "sections" : [
                              {"title": "MOA", "content": "Blocks SET and NET on pre-synaptic neuron resulting in increased levels of serotonin and norepinephrine in the synapse. Some also acts as antagonists at 5HT2, Alpha1-adrenergic, histamine and muscarinic receptors." },
                              {"title": "SAR", "imagePath": "triptyline.PNG", "content": ""},
                              {"title": "SAR Explained", "content": "[Linker of 3 carbons]: between tricyclic ring system and basic nitrogen. Branching from linker decreases binding affinity for SERT and NET. Unsaturation of linker is tolerated. [R→ CH3]: tertiary amine imparts selectivity for SERT. [R’→ Cl or CN (EWG)]: enhances binding affinity for SERT. [Y→ can be C or N]. [Conformationally rigid [6.7.6]-fused ring system]: 7 membered ring in the middle is not coplanar; results in twisted shape"},
                              {"title": "Side Effects", "content": "[Major]: Weight gain, GI, Sexual Effect."}
                        ]
                  },
                  {
                        "title": "THEORIES OF DEPRESSION",  
                        "sections" : [
                              {"title": "Monoamine Theory", "content": "Deficiency of 5-HT and NE transmission in the CNS"},
                              {"title": "Neurotrophic Theory", "content": "Decrease of Brain Derived Neurotophic Factor (BDNF) resulting in reduced neuroplasticity, decreased number of spines and thus, decreased neurotransmission."}
                        ]
                  },
                  {
                        "title": "LOW NERUOTRANSMITTER LEVELS",  
                        "sections" : [
                              {"title": "Low serotonin", "content": "Anxiety, panic, phobia"},
                              {"title": "Low norepinephrine", "content": "Decreased concentration, decreased working memory, decreased information processing, fatigue."},
                              {"title": "Low dopamine", "content": "Cognitive slowing, hypersomnia, anhedonia"}
                        ]
                  },
                  {
                        "title": "ACTIVATION OF RECEPTORS",  
                        "sections" : [
                              {"title": "5-HT", "content": "GI and Nausea, Sexual Effects (decreased libido, sexual dysfunction), Mild Restlessness, Headaches and Insomnia"},
                              {"title": "Adrenergic", "content": "Agitation (awakening), small increases in blood pressure and heart rate"},
                              {"title": "Antihistamine H1", "content": "Sedation"},
                              {"title": "Alpha1-Adrenergic", "content": "Hypotension"}
                        ]
                  }

            ]            
      },
      {
            "id": 9,
            "name": "CWB-Inhibitors",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Fosfomycin: Hover over compound to view areas.",
                        "imagePath" : "slide2-fosfomycin.PNG",
                        "imgWidth" : 300,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Reactive Epoxide Group",
                                    "y": 210,
                                    "x": 262,
                                    "size": 55,
                                    "color": "blue",
                                    "text": "Reactive Epoxide Group"
                              },
                              {
                                    "name": "PEP Mimic",
                                    "y": 270,
                                    "x": 142,
                                    "size": 75,
                                    "color": "red",
                                    "text": "PEP Mimic"
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cycloserine: Hover over compound to view areas.",
                        "imagePath" : "slide2-cycloserine.PNG",
                        "compoundHotspots" : [
                              {
                                    "name": "D-Ala analogue",
                                    "y": 260,
                                    "x": 154,
                                    "size": 120,
                                    "color": "red",
                                    "text": "D-Ala analogue"
                              },
                              {
                                    "name": "5-membered ring",
                                    "y": 254,
                                    "x": 264,
                                    "size": 50,
                                    "color": "blue",
                                    "text": "5-membered ring"
                              }
                        ]
                        
                  },
                  {
                        "title": "D Alanine & D Cycloserine",
                        "name": "Click 'Play' or drag the compounds.",
                        "options": [
                              {
                                    "canvasSize": { "width": 400, "height": 600 }
                              }
                        ],
                        "objects": [
                              { 
                                    "image": "d-alanine-overlay.PNG", 
                                    "startY": 10, 
                                    "startX": 10, 
                                    "opacity": ".5", 
                                    "movementLocked": "x",
                                    "controlLocked": "all",
                                    "text": {
                                          "value": "D Alanine",
                                          "left": 0,
                                          "top": -100,
                                          "fontSize": 30
                                    },
                                    "movement":
                                          {
                                                "destination": { "x": 150, "y":157 },
                                                "on": ""
                                          }
                              },
                              { 
                                    "image": "d-cycloserine-overlay.PNG", 
                                    "startY": 400, 
                                    "startX": 20, 
                                    "opacity": ".5", 
                                    "movementLocked": "x",
                                    "controlLocked": "all",
                                    "text": {
                                          "value": "D Cycloserine",
                                          "left": 0,
                                          "top": 100,
                                          "fontSize": 30
                                    },
                                    "movement":
                                          {
                                                "destination": { "x": 160, "y":200 },
                                                "on": ""
                                          }
                              }
                        ]
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Bacitracin: Hover over compound to view areas.",
                        "imagePath" : "slide3-bacitracin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 75,
                        "compoundHotspots" : [
                              {
                                    "name": "Peptide Bond",
                                    "y": 310,
                                    "x": 207,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Bacitracin contains many peptide bonds"
                              },
                              {
                                    "name": "Peptide Bond",
                                    "y": 310,
                                    "x": 323,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Bacitracin contains many peptide bonds"
                              }
                        ]
                        
                  },
                                    {
                        "title":"SAR Requirements",  
                        "name" : "Vancomycin: Hover over compound to view areas.",
                        "imagePath" : "slide4-vancomycin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Peptide Bond",
                                    "y": 216,
                                    "x": 435,
                                    "size": 30,
                                    "color": "blue",
                                    "text": "Vancomycin contains many peptide bonds"
                              },
                               {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 233,
                                    "x": 410,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                              {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 320,
                                    "x": 394,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                               {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 386,
                                    "x": 387,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              },
                              {
                                    "name": "H-Bond with D-Ala-D-Ala",
                                    "y": 544,
                                    "x": 306,
                                    "size": 20,
                                    "color": "red",
                                    "text": "This atom forms hydrogen bonds with D-Ala-D-Ala"
                              }
                        ]
                        
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide5-9.PNG",
                        "question" : "Which compound below interferes with peptide cross-linking?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) Binds directly to the D-Ala-D-Ala terminal to prevent peptide cross-linking."
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits the conversion of UDP-NAG→ UDP-NAM?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Fosfomycin (Compound 2) Results in irreversible alkylation of the active cysteine on MurA."
                  },
                  {
                        "title":"Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits Ala racemase & D-Ala ligase?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Cycloserine (Compound 3) Prevents conversion of L-Ala→ D-Ala and the joining of D-Ala & D-Ala."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide6-7-8.PNG",
                        "question" : "Which compound below inhibits pyrophosphatase?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Bacitracin (Compound 1) Inhibits the recycling of bactoprene molecule."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide5-9.PNG",
                        "question" : "GT is diagnosed with C. difficile. Which oral antibiotic would be best to treat his infection?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) is not orally absorbed, so it will stay in the gut to treat the infection in the large intestine"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide10-11.PNG",
                        "question" : "SM is diagnosed with a UTI infection. Which compound would be best to treat his infection and has few side effects?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Fosfomycin (Compound 2) is indicated for urinary tract infections, and is especially active against E. Coli"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide10-11.PNG",
                        "question" : "GT has a history of psychosis. Which antibiotic below is best avoided in this patient?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Cycloserine (Compound 1) acts as a partial agonist at the NMDA receptor can result in dose-dependent neurologic and psychiatric disturbances."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide12-13.PNG",
                        "question" : "BK has kidney dysfunction. Which 2 antibiotics below have side effects that would be harmful to this patient?",
                        "options" : [
                              "Compound 1 & 2", 
                              "Compound 1 & 3", 
                              "Compound 2 & 3"
                        ],
                        "answer" : "Compound 1 & 3",
                        "explanation" : "Bacitracin (Compound 1) and vancomycin (Compound 3) can both result in nephrotoxicity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study ",
                        "imagePath" : "slide12-13.PNG",
                        "question" : "AM’s bacterial infection is not responding to treatment. The bacteria in her body have become resistant to the antibiotic by producing D-Ala-D-Lac. Which of the antibiotics was she taking?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Vancomycin (Compound 3) normally binds to D-Ala-D-Ala of the pentapeptide tail, but with this change to D-Ala-D-Lac, it can no longer bind."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Gram positive bacteria have ___________ in their cell wall that determine its rigidity and __________ to regulate cation movement.",
                        "options" : [
                              "teichoic acid, peptidoglycan",
                              "cellulose, teichoic acid",
                              "peptidoglycan, porins",
                              "cellulose, porins", 
                              "peptidoglycan, teichoic acid"
                        ],
                        "answer" : "peptidoglycan, teichoic acid"
                  },
                  {
                        "title":"",  
                        "question" : "In Gram negative bacteria the area between the cytoplasmic membrane and thin layer of peptidoglycan is called the ___________.",
                        "options" : [
                              "pericardium space",
                              "endoplasmic space",
                              "periplasmic space",
                              "pleuraplasmic space"
                        ],
                        "answer" : "periplasmic space"
                  },
                  {
                        "title":"",  
                        "question" : "Source of acetate in N-acetyl glucosamine (NAG) is _________.",
                        "options" : [
                              "MurA",
                              "pyrophosphatase",
                              "phosphoenolpyruvate",
                              "acetyl CoA"
                        ],
                        "answer" : "acetyl CoA"
                  },
                  {
                        "title":"",  
                        "question" : "__________ is an irreversible inhibitor of MurA and targets the enzyme UDP-NAG Transferase",
                        "options" : [
                              "Cycloserin",
                              "Bactoprene",
                              "Fosfomycin",
                              "Nitrofurantoin"
                        ],
                        "answer" : "Fosfomycin"
                  },
                  {
                        "title":"",  
                        "question" : "Fosfomycin is indicated for ___________",
                        "options" : [
                              "meningitis",
                              "UTI",
                              "pneumonia",
                              "yeast infection"
                              
                        ],
                        "answer" : "UTI"
                  },
                  {
                        "title":"",  
                        "question" : "_____________ is a reversible competitive inhibitor of Alanine racemase and D-Ala D-Ala ligase",
                        "options" : [
                              "Fosfomycin",
                              "Bacitracin",
                              "Vancomycin",
                              "Cycloserine"
                        ],
                        "answer" : "Cycloserine"
                  },
                  {
                        "title":"",  
                        "question" : "A serious side effect of cycloserine is ____________ caused by NMDA binding",
                        "options" : [
                              "muscle aches",
                              "ototoxicity",
                              "nephrotoxicity",
                              "neurotoxicity"
                        ],
                        "answer" : "neurotoxicity"
                  },
                  {
                        "title":"",  
                        "question" : "_________ binds to pyrophosphatase and prevents regeneration of _________",
                        "options" : [
                              "Bactoprene, Bacitracin",
                              "Bacitracin, Bactoprene",
                              "Vancomycin, Acetyl coA",
                              "Cycloserine, Acetyl coA",
                              "Bacitracin, Peptidoglycan",
                              "Vancomycin, Peptidoglycan"
                        ],
                        "answer" : "Bacitracin, Bactoprene"
                  },
                  {
                        "title":"",  
                        "question" : "Vancomycin binds to peptidoglycan to prevent crosslinking. Resistance to Vancomycin occurs through a change in structure of peptidoglycan from an ___________.",
                        "options" : [
                              "ester, to an amide",
                              "amide to an ester",
                              "amine to an ester",
                              "amide to an ether",
                              "amide to an ether"
                        ],
                        "answer" : "amide to an ester"
                  },
                  {
                        "title":"",  
                        "question" : "Vancomycin is not orally absorbed but can treat ___________",
                        "options" : [
                              "Meningitis",
                              "UTI",
                              "C. Diff Infections",
                              "Pheumonia"
                        ],
                        "answer" : "C. Diff Infections"
                  },
                  {
                        "title":"",  
                        "question" : "To avoid the side effect ___________, vancomycin should be infused _________",
                        "options" : [
                              "Steven’s Johnson Syndrome, slowly",
                              "Reye’s Syndrome, rapidly",
                              "Red Man Syndrome, slowly",
                              "Extrapyramidal symptoms, rapidly"
                        ],
                        "answer" : "Red Man Syndrome, slowly"
                  },
                  {
                        "title":"",  
                        "question" : "Daptomycin cannot be used for ________ because of inactivation by surfactants",
                        "options" : [
                              "UTI",
                              "Pneumonia",
                              "Otitis",
                              "Sinusitis"
                        ],
                        "answer" : "Pneumonia"
                  }
            ],
             "reviewItems":[
                  {
                        "title": "Fosfomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fosfomycin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Cycloserine",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cycloserine.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Bacitracin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "bacitracin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Vancomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "vancomycin.PNG" },
                              {"title": "SAR", "content": "" },
                              {"title": "Type of Inhibitor", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicities", "content": ""}
                        ]
                  }
            ],                     
            "exampleReview":[
                  {
                        "title": "Fosfomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fosfomycin.PNG" },
                              {"title": "SAR", "content": "PEP mimic, Reactive epoxide group" },
                              {"title": "Type of Inhibitor", "content": "Irreversible inhibitor/Suicide inhibitor"},
                              {"title": "MOA & Target", "content": "MOA: Inhibits PEP which inhibits cell peptidoglycan synthesis - specifically NAM synthesis (Stage 1: Synthesis of Building Blocks) Bactericidal Target: UDP-NAG phosphoenoylpyruvuyl (PEP) transferase = MurA"},
                              {"title": "MOR", "content": "1) Mutation of active site (Microbe has Cysteine instead of Asp) 2) Mutation of glycerophosphate transporter"},
                              {"title": "Spectrum", "content": "Broad – both Gram positive and Gram negative"},
                              {"title": "Toxicities", "content": "Low Nausea, vomiting, diarrhea, hypersensitivity, skin rash"}
                        ]
                  },
                  {
                        "title": "Cycloserine",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cycloserine.PNG" },
                              {"title": "SAR", "content": "D-Ala analogue, 5-membered ring" },
                              {"title": "Type of Inhibitor", "content": "Non-covalent/competitive inhibitor – substrate mimic Binds 100x more tightly to the enzymes (rigid structure)"},
                              {"title": "MOA & Target", "content": "MOA; Competitive inhibitor of racemase Which inhibits cell peptidoglycan synthesis. (Stage 1: Synthesis of Building Blocks) Bactericidal Target: D-Ala-D-Ala racemase and D-Ala-D-Ala ligase"},
                              {"title": "MOR", "content": "Overexpression of  D-alanine racemase (AlrA)"},
                              {"title": "Spectrum", "content": "Broad – both Gram positive and Gram negative"},
                              {"title": "Toxicities", "content": "Neurotoxic CNS disturbance, anxiety, confusion and drowsiness"}
                        ]
                  },
                  {
                        "title": "Bacitracin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "bacitracin.PNG" },
                              {"title": "SAR", "content": "Large molecule with many peptide bonds" },
                              {"title": "Type of Inhibitor", "content": "N/A"},
                              {"title": "MOA & Target", "content": "MOA: Binds to pyrophosphatase in the presence of Magnesium,thus preventing regeneration of Bactoprene. It is more active if zinc is already present in the preparation, aiding in the binding to pyrophosphatase which inhibits cell peptidoglycan synthesis. (Stage 2: Synthesis of Membrane-bound Precursors and Polymerization) Bactericidal Target: Pyrophosphatases"},
                              {"title": "MOR", "content": "Failure to penetrate membrane"},
                              {"title": "Spectrum", "content": "Gram positive only – too big to get through outer membrane of Gram negative"},
                              {"title": "Toxicities", "content": "Nephrotoxicity – not used systemically. For topical use only."}
                        ]
                  },
                  {
                        "title": "Vancomycin",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "vancomycin.PNG" },
                              {"title": "SAR", "content": "Large molecule with many peptide bonds - Circled atoms form hydrogen bonds with D-Ala-D-Ala" },
                              {"title": "Type of Inhibitor", "content": "Competitive/Reversible"},
                              {"title": "MOA & Target", "content": "(Stage 2: Synthesis of Membrane-bound Precursors and Polymerization) Binds directly to the D-Ala-D-Ala terminal to prevent peptide cross-linking Bactericidal Target:  D-Ala-D-Ala"},
                              {"title": "MOR", "content": "1. Alter the substrate – make D-Ala-D-Lac. Results in loss of H-bond between vancomycin and dipeptide. 2.  Thicker cell wall of bacterium"},
                              {"title": "Spectrum", "content": " Gram positive only"},
                              {"title": "Toxicities", "content": "Redman syndrome (if infused too quickly), Nephrotoxicity, Hearing loss, Rash"}
                        ]
                  }
            ]            
      },
      {
            "id": 10,
            "name": "Beta-Lactams",
            "learnItems":[
                  {
                        "title":"SAR Requirements",  
                        "name" : "Penicillin: Hover over compound to view areas.",
                        "imagePath" : "slide2-penicillin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "β-Lactam Ring",
                                    "y": 287,
                                    "x": 400,
                                    "size": 40,
                                    "color": "black",
                                    "text": "β-Lactam Ring & Fused Bicyclic System: Creates a strained system (but less strain than the penicillins, so less reactive)"
                              },
                              {
                                    "name": "Position 1",
                                    "y": 340,
                                    "x": 437,
                                    "size": 35,
                                    "color": "green",
                                    "text": "Must be a nitrogen"
                              },
                              {
                                    "name": "Position 2",
                                    "y": 423,
                                    "x": 550,
                                    "size": 90,
                                    "color": "blue",
                                    "text": "Must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site"
                              },
                              {
                                    "name": "Position 3",
                                    "y": 280,
                                    "x": 588,
                                    "size": 55,
                                    "color": "darkorange",
                                    "text": "Any change will lower activity"
                              },
                              {
                                    "name": "Position 4",
                                    "y": 209,
                                    "x": 512,
                                    "size": 45,
                                    "color": "purple",
                                    "text": "Sulfur is usual, but not essential"
                              },
                              {
                                    "name": "Position 5",
                                    "y": 192,
                                    "x": 397,
                                    "size": 70,
                                    "color": "deeppink",
                                    "text": "No substitutions allowed; cis stereochemistry with hydrogens at position 5 & 6 is essential"
                              },
                              {
                                    "name": "R Group",
                                    "y": 215,
                                    "x": 182,
                                    "size": 40,
                                    "color": "grey",
                                    "text": "EWG: increases the acid stability of the compound. Bulky group: directly attached to the amide will make the compound more B-lactamase resistant. Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria"
                              },
                              {
                                    "name": "Position 7",
                                    "y": 360,
                                    "x": 333,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Must be a carbonyl"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cephalosporin: Hover over compound to view areas.",
                        "imagePath" : "slide4-cephalosporin.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "β-Lactam Ring",
                                    "y": 271,
                                    "x": 404,
                                    "size": 35,
                                    "color": "black",
                                    "text": "β-Lactam Ring & Fused Bicyclic System: Creates a strained system."
                              },
                              {
                                    "name": "Position 1",
                                    "y": 320,
                                    "x": 438,
                                    "size": 35,
                                    "color": "green",
                                    "text": "Must be a nitrogen"
                              },
                              {
                                    "name": "Position 2",
                                    "y": 403,
                                    "x": 516,
                                    "size": 70,
                                    "color": "blue",
                                    "text": "Must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site"
                              },
                              {
                                    "name": "Position 3",
                                    "y": 319,
                                    "x": 604,
                                    "size": 70,
                                    "color": "darkorange",
                                    "text": "R2 Group: Non-metabolized group: increases oral activity & acid stability. MTT group: extended spectrum, longer-half life, higher potency. Pyrimidine ring (positive charge): forms a zwitterion & increases solubility. 1,3 thiazole ring: Anti-MRSA activity"
                              },
                              {
                                    "name": "Position 5",
                                    "y": 185,
                                    "x": 497,
                                    "size": 38,
                                    "color": "purple",
                                    "text": "Sulfur is usual, but not essential"
                              },
                              {
                                    "name": "Position 6",
                                    "y": 200,
                                    "x": 437,
                                    "size": 45,
                                    "color": "deeppink",
                                    "text": "No substitutions allowed"
                              },
                              {
                                    "name": "R1 Group",
                                    "y": 215,
                                    "x": 182,
                                    "size": 40,
                                    "color": "grey",
                                    "text": "EWG: increases the acid stability of the compound. Bulky group: directly attached to the amide will make the compound more B-lactamase resistant. Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria. Oxime: increases B-lactamase resistance."
                              },
                              {
                                    "name": "Position 7",
                                    "y": 195,
                                    "x": 369,
                                    "size": 45,
                                    "color": "brown",
                                    "text": "R3 group: Addition of OCH3 (7-alpha-methoxy) increases B-lactamase resistance"
                              },
                              {
                                    "name": "Position 8",
                                    "y": 353,
                                    "x": 340,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Must be a carbonyl"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Requirements",  
                        "name" : "Cephalosporin / Ceftaroline: Hover over compound to view areas.",
                        "imagePath" : "ceftaroline.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 169,
                                    "x": 136,
                                    "size": 50,
                                    "color": "orangered",
                                    "text": "Info: Specific requirements for Ceftaroline (5th generation) to be aware of"
                              }
                        ]
                        
                  },
                  {
                        "title":"Other β-lactam Classes",  
                        "name" : "Carbapenems: Hover over Imipenem to view areas.",
                        "imagePath" : "imipenem.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 286,
                                    "x": 340,
                                    "size": 85,
                                    "color": "orangered",
                                    "text": "Unsaturated 5-membered ring connected to the β-lactam ring"
                              }
                        ]
                        
                  },
                  {
                        "title":"Other β-lactam Classes",  
                        "name" : "Monobactams: Hover over Aztreonam to view areas.",
                        "imagePath" : "aztreonam.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 317,
                                    "x": 442,
                                    "size": 50,
                                    "color": "orangered",
                                    "text": "Only a single B-lactam ring"
                              }
                        ]
                        
                  },
                  {
                        "title":"β-lactamase Inhibitors",  
                        "name" : "Hover over each molecule to view names.",
                        "imagePath" : "exampleInhibitors.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "Clavulanic Acid",
                                    "y": 215,
                                    "x": 270,
                                    "size": 115,
                                    "color": "red",
                                    "text": "Clavulanic Acid"
                              },
                              {
                                    "name": "Avibactam",
                                    "y": 406,
                                    "x": 543,
                                    "size": 115,
                                    "color": "blue",
                                    "text": "Avibactam"
                              },
                              {
                                    "name": "Sulbactam",
                                    "y": 404,
                                    "x": 263,
                                    "size": 115,
                                    "color": "darkorange",
                                    "text": "Sulbactam"
                              },
                              {
                                    "name": "Tazobactam",
                                    "y": 228,
                                    "x": 533,
                                    "size": 115,
                                    "color": "purple",
                                    "text": "Tazobactam"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide8-9-10.PNG",
                        "question" : "Which addition to amide side chain (R) broadens the spectrum of penicillins?",
                        "options" : [
                              "Bulky group", 
                              "Heterocyclic ring", 
                              "Polar group",
                              "Electron withdrawing group"
                        ],
                        "answer" : "Polar group",
                        "explanation" : "No explanation provided."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide8-9-10.PNG",
                        "question" : "Which addition to amide side chain (R) makes penicillins more acid stable?",
                        "options" : [
                              "Bulky group", 
                              "Heterocyclic ring", 
                              "Polar group",
                              "Electron withdrawing group"
                        ],
                        "answer" : "Electron withdrawing group",
                        "explanation" : "No explanation provided."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide8-9-10.PNG",
                        "question" : "Which addition to amide side chain (R) makes penicillins less susceptible to B-lactamases?",
                        "options" : [
                              "Bulky group", 
                              "Heterocyclic ring", 
                              "Polar group",
                              "Electron withdrawing group"
                        ],
                        "answer" : "Bulky group",
                        "explanation" : "No explanation provided."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide11.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Sulfate group essential for activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide12.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Carboxylic acid essential for activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide13.PNG",
                        "question" : "Which compound(s) are acid stable and can be taken orally?",
                        "options" : [
                             "Compound 1 & 3",
                             "Compound 2 & 3", 
                             "Compound 1 & 2"
                        ],
                        "answer" : "Compound 1 & 2",
                        "explanation" : "Both compound 1 (cefaclor) & compound 2 (cefdinir) contain non-metabolizable groups at position 3."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide14.PNG",
                        "question" : "Which compound(s) has increased β-lactamase resistance?",
                        "options" : [
                              "Compound 1 & 3",
                              "Compound 2 & 3", 
                              "Compound 1 & 2"
                        ],
                        "answer" : "Compound 1 & 2",
                        "explanation" : "Both compound 1 (cefepime) and compound 2 (cefdinir) contains oxime group as R1"
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide15.PNG",
                        "question" : "Which compound has increased β-lactamase resistance?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 3 (cefotetan) Contains 7-alpha-methoxy group."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide16.PNG",
                        "question" : "Which compound is most active against staph infections?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2 (methicillin) contain non-metabolizable groups at position."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide17.PNG",
                        "question" : "Which compound shows the highest oral bioavailability?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1 (amoxicillin) contains polar R group and does not form a Zwitterion around pH of the GIT. "
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide18.PNG",
                        "question" : "Which compound is associated with Disulfiram-like reaction?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2 (cefamandole) because R2- contains MTT ring."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide19.PNG",
                        "question" : "Which compound is NOT used with β-lactamase inhibitors?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 3 (nafcillin) contains bulky R group directly attached to amide."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide20.PNG",
                        "question" : "Which compound shows the least amount of antimicrobial activity?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2 (clavulanic acid) β-lactamase inhibitor; no antimicrobial activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide21.PNG",
                        "question" : "Which compound must be used in combination with cilastin?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2 (imipenem) is hydrolyzed by dehydropeptidase in the kidney to a nephrotoxic metabolite. Cilastin inhibits dehydropeptisdase."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide22.PNG",
                        "question" : "GM is experienced a life-threatening reaction from amoxicillin, which antibiotic is safe for this patient to use?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 3 (aztreonam) because no cross-allergic reactions with other β-lactams."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide23.PNG",
                        "question" : "Which compound(s) are acid stable and can be taken orally?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1 (ceftriaxone) contains heterocyclic ring, which broadens spectrum and increases anti-pseudomonal activity."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Penicillins bind and inhibit __________ to prevent crosslinking.",
                        "options" : [
                              "Ligases",
                              "Mur A",
                              "Pyrophosphatases",
                              "Penicillin Binding Proteins (PBP)"
                        ],
                        "answer" : "Penicillin Binding Proteins (PBP)"
                  },
                  {
                        "title":"",  
                        "question" : "Resistance to penicillins develops quickly due to ________ or PBP mutations",
                        "options" : [
                              "β-lactamases",
                              "acid-base condition changes",
                              "alteration of side chains"
                        ],
                        "answer" : "β-lactamases"
                  },
                  {
                        "title":"",  
                        "question" : "Clavulanic acid, Sulbactam, and Tazobactam are all examples of β-lactamase ________.",
                        "options" : [
                              "inducers",
                              "inhibitors",
                              "producers"
                        ],
                        "answer" : "inhibitors"
                  },
                  {
                        "title":"",  
                        "question" : "_________ is combined with imipenem to avoid degradation in the kidney.",
                        "options" : [
                              "Polymixin",
                              "Colistin",
                              "Cilastatin",
                              "Clavulanic acid "
                        ],
                        "answer" : "Cilastatin"
                  },
                  {
                        "title":"",  
                        "question" : "Carbapenem resistant Enterobacteriaceae (CRE) can be treated with polymixin and ______. ",
                        "options" : [
                              "cilastatin",
                              "clavulanic acid",
                              "sulbactam",
                              "colistin"
                        ],
                        "answer" : "colistin"
                  },
                  {
                        "title":"",  
                        "question" : "Carbapenems cannot be combined with _________. ",
                        "options" : [
                              "tetracyclines",
                              "other beta lactams",
                              "aminoglycosides",
                              "macrolides"
                        ],
                        "answer" : "aminoglycosides"
                  },
                  {
                        "title":"",  
                        "question" : "Cephalosporins are inherently ____ active than Penicillins but are ____ resistant to β-lactamases.",
                        "options" : [
                              "less, more",
                              "more, less",
                              "more, not"
                        ],
                        "answer" : "less, more"
                  },
                  {
                        "title":"",  
                        "question" : "Cephalosporins substituted with a _______ can extend the spectrum but also cause side effects such as _______ and Disulfiram-like effect.",
                        "options" : [
                              "amide, hemolytic anemia",
                              "ester, thrombocytosis",
                              "sulfa group, leukopenia",
                              "MTT group, hypothrombocytopenia"
                        ],
                        "answer" : "MTT group, hypothrombocytopenia"
                  },
                  {
                        "title":"",  
                        "question" : "_______ are mostly reserved for serious Gram-negative infections such as meningitis.",
                        "options" : [
                              "Carbapenems",
                              "Beta Lactams",
                              "Aminoglycosides",
                              "Monobactams"
                        ],
                        "answer" : "Monobactams"
                  },
                  {
                        "title":"",  
                        "question" : "_______ is an inhalent to treat chronic pseudomonas infections with CF patients, has activity against pseudomonas because it has the same side chain as _______.",
                        "options" : [
                              "Imipenem, cefixime",
                              "Meropenem, ceftaxime",
                              "Aztreonam, ceftazidine",
                              "Ertapenem, cephalexin"
                        ],
                        "answer" : "Aztreonam, ceftazidine"
                  }
            ],
             "reviewItems":[
                   {
                        "title": "Beta Lactamase Inhibitor",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "BetaLactamaseInhibitor.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""}
                        ]
                  },
                   {
                        "title": "Monobactam",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "monobactam.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum & Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Carbapenem",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "carbapenem.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum & Toxicities", "content": ""}
                        ]
                  },
                   {
                        "title": "Penicillins",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cephalosporins.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum, Target, Type, & Toxicities", "content": ""}
                        ]
                  },
                  {
                        "title": "Cephalosporins",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "cephalosporins.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum, Target, Type, & Toxicities", "content": ""}
                        ]
                  }
            ],      
            "exampleReview":[
                  {
                        "title": "Beta Lactamase Inhibitor",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "BetaLactamaseInhibitor.PNG" },
                              {"title": "SAR", "content": "-β-lactam ring (tetracyclic amide) is essential. -Any modification to β-lactam ring results in inactivation"},
                              {"title": "MOA", "content": "Irreversible, 'suicide' inhibitor of many (but not all) bacterial β-lactamases. Covalently bind to serine residue of active site of β-lactamases"},
                              {"title": "Spectrum", "content": "No antimicrobial activity. Used in combination with penicillins to increase spectrum of activity"}
                        ]
                  },
                  {
                        "title": "Monobactam",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "monobactam.PNG" },
                              {"title": "SAR", "content": "- Single β-lactam ring. -A methyl group can be placed at R2 for β-lactamase stability. -R1 can be changed to an extent to improve spectrum and activity. -SO3 group facilitates ring opening. -Methoxy group improves β-lactamase stability but decreases ring stability"},
                              {"title": "MOA", "content": "Interferes with bactericidal cell wall synthesis by binding to and inactivating penicillin-binding-proteins. This binding causes the formation of elongation or bacterial filamentation resulting in cell lysis and cell death. Bactericidal"},
                              {"title": "MOR", "content": "Resistance to aztreonam is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability."},
                              {"title": "Spectrum & Toxicities", "content": "Spectrum: Gram negative. Toxicities: Rash, diarrhea"}
                        ]
                  },
                  {
                        "title": "Carbapenem",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "carbapenem.PNG" },
                              {"title": "SAR", "content": "-Unsaturated 5-membered ring connected to the β-lactam ring. -β-lactam ring and COOH are essential for function. -R1 and R2 are variable regions that can alter spectrum, susceptibility to lactamases and stability."},
                              {"title": "MOA", "content": "Cause rapid bacterial cell death by covalently binding to penicillin-binding proteins (PBPs) involved in the biosynthesis of mucopeptides in bacterial cell walls.  Bactericidal effects result through inhibition of cellular growth and division and the loss of cell wall integrity, eventually causing cell wall lysis. The primary target is PBP-2."},
                              {"title": "MOR", "content": "1. Modified porins 2. Efflux pumps 3. Synthesis of inactivating enzymes (very uncommon)"},
                              {"title": "Spectrum & Toxicities", "content": "Spectrum: Broadest spectrum (gram positive and negative). Toxicities: GI, Renal insufficiency, Hepatic insufficiency, Anemia"}
                        ]
                  },
                  {
                        "title": "Penicillins",
                        "sections": [{
                              "title": "Compound",
                              "imagePath": "penicillins.PNG"
                        }, {
                              "title": "SAR",
                              "content": "β-lactam ring & fused bicyclic system: creates a strained system. -Position 1: must be a nitrogen. -Position 2: must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site. -Position 3: any change will lower activity. Position 4: sulfur is usual, but not essential. Position 5: no substitutions allowed; cis stereochemistry with hydrogens at position 5 & 6 is essential. [R Group]: EWG: increases the acid stability of the compound. Bulky group: directly attached to the amide will make the compound more β-lactamase resistant. Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria. Position 7: must be a carbonyl"
                        }, {
                              "title": "MOA",
                              "content": "Inhibits cell peptidoglycan synthesis – specifically crosslinking of peptidoglycan strands. Bactericidal"
                        }, {
                              "title": "MOR",
                              "content": "1. Synthesis of inactivating enzymes ->  β-lactamases  (less common in cephalosporin’s) 2. Mutations to PBP (decreases affinity of drug to target). 3. Alternation of porins (decrease ability of drug to reach site of action in bacteria)."
                        }, {
                              "title": "Spectrum, Target, Type, & Toxicities",
                              "content": "[Spectrum]: Early penicillin’s gram positive only, but as a class they are broad spectrum. [Target]: Penicillin Binding Proteins (PBPs). [Inhibitor Type]: Irreversible covalent inhibitor/ suicide inhibitor – substrate mimic. [Toxicities]:Immune response (low incidence), nephrotoxicity, pseudomonas colitis, seizures."
                        }]
                  },
                  {
                        "title": "Cephalosporins",
                        "sections": [{
                              "title": "Compound",
                              "imagePath": "cephalosporins.PNG"
                        }, {
                              "title": "SAR",
                              "content": "[β-lactam ring & fused bicyclic system]: creates a strained system (but less strain than the penicillins, so less reactive). [Position 1]: must be a nitrogen. [Position 2]: must be a carboxylic acid for activity; binds to charged nitrogen of a lysine residue in the binding site. [Position 3]: R2 group: -Non-metabolized group: increases oral activity & acid stability. MTT group: extended spectrum, longer-half life, higher potency. -Pyrimidine ring (positive charge): forms a zwitterion & increases solubility. -1,3 thiazole ring: Anti-MRSA activity. [Position 5]: sulfur is usual, but not essential. [Position 6]: no substitutions allowed. [Position 7]: R3 group-addition of OCH3 (7-alpha-methoxy) increases β-lactamase resistance. [R1 group]: -EWG: increases the acid stability of the compound. -Bulky group: directly attached to the amide will make the compound more β-lactamase resistant. -Polar group: broadens the spectrum as this allows the compound to pass through the porins of gram negative bacteria. -Oxime: increases β-lactamase resistance. [Position 8]: must be a carbonyl."
                        }, {
                              "title": "MOA",
                              "content": "Inhibits cell peptidoglycan synthesis – specifically crosslinking of peptidoglycan strands. Bactericidal"
                        }, {
                              "title": "MOR",
                              "content": "1. Synthesis of inactivating enzymes ->  β-lactamases  (less common in cephalosporin’s) 2. Mutations to PBP (decreases affinity of drug to target). 3. Alternation of porins (decrease ability of drug to reach site of action in bacteria)."
                        }, {
                              "title": "Spectrum, Target, Type, & Toxicities",
                              "content": "[Spectrum]: Dependent on generation, some have very broad spectrum – even effective against organisms that produce β-lactamases. [Target]: Penicillin Binding Proteins (PBPs). [Inhibitor Type]: Irreversible covalent inhibitor – suicide inhibitors. [Toxicities]: Immune response (cross reactivity with other β-lactams) – otherwise low, nephrotoxicity, pseudomonas colitis, seizures. A-Typical side effects due to MTT group: Hypothrombocytopenia, Disulfiram-like effect"
                        }]
                  }
            ]            
      },
      {
            "id": 11,
            "name": "FAB-Inhibitors",
            "learnItems":[
                  {
                        "title":"Sulfonamides",  
                        "name" : "Hover over the molecule to view SAR Requirements.",
                        "imagePath" : "sulfonamidesSAR.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "Amine",
                                    "y": 248,
                                    "x": 205,
                                    "size": 75,
                                    "color": "blue",
                                    "text": "Amine is essential: Must be un-substituted, Must be para to the sulfonamide"
                              },
                              {
                                    "name": "Benzene Ring",
                                    "y": 248,
                                    "x": 375,
                                    "size": 90,
                                    "color": "red",
                                    "text": "Benzene ring is essential"
                              },
                              {
                                    "name": "Sulfonamide",
                                    "y": 248,
                                    "x": 550,
                                    "size": 100,
                                    "color": "green",
                                    "text": "Sulfonamide is essential: Must be un-ionized to cross bacterial cell membrane, Must be ionized to interact with DHPS active site, Mono-substitution allowed (EWG & heterocycle are favorable), Di-substitution abolishes activity, Must be para to the amine."
                              }
                        ]
                        
                  },
                  {
                        "title":"Trimethoprim",  
                        "name" : "Hover over Trimethoprim to view characteristic parts.",
                        "imagePath" : "trimethoprimSAR.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "",
                                    "y": 222,
                                    "x": 263,
                                    "size": 115,
                                    "color": "red",
                                    "text": "First Characteristic part of Trimethoprim"
                              },
                              {
                                    "name": "",
                                    "y": 360,
                                    "x": 433,
                                    "size": 130,
                                    "color": "red",
                                    "text": "Second Characteristic part of Trimethoprim"
                              }
                        ]
                        
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide4.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Addition of heterocycle to sulfonamide is favorable and decreases pH to optimal range."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide5.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Amine essential for activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide6.PNG",
                        "question" : "Which of the two compounds has greatest antimicrobial activity?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "The negative charge on the sulfonamide can be stabilized by resonance with the ring."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide7.PNG",
                        "question" : "Which is a prodrug?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1 (prontosil) Metabolized by reductases to give active form of sulfonamide."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide8.PNG",
                        "question" : "Which is the longest acting sulfonamide?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Compound 2 (sulfadoxine) Has a half life of 150 hours."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the correct answer",
                        "imagePath" : "slide9.PNG",
                        "question" : "Which characteristics, at physiological pH, would provide the most effective sulfonamide?",
                        "options" : [
                              "Low lipophilicity, unionized", 
                              "High lipophilicity, unionized",
                              "Low lipophilicity, ionized",
                              "High lipophilicity, ionized"
                        ],
                        "answer" : "High lipophilicity, ionized",
                        "explanation" : "Lipophilicity is needed to enter the cell and ionization is required to bind to enzyme."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide10.PNG",
                        "question" : "Which of the following inhibits DHPS?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1 is sulfamethoxazole."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Mechanism of Action",
                        "imagePath" : "slide11.PNG",
                        "question" : "Which of the following inhibits DHFR?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Compound 1 is trimethoprim."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide12.PNG",
                        "question" : "KT has a history of Steven Johnson Syndrome, which antibiotic is best avoided in her?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Compound 3 (sulfamethoxazole) is a sulfonamide which can lead to this life-threatening rash."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Sulfonamides can be slow to act because you must deplete the _______ pool before seeing an effect.",
                        "options" : [
                              "glutathione",
                              "sulfa",
                              "folate",
                              "DHPS"
                        ],
                        "answer" : "folate"
                  },
                  {
                        "title":"",  
                        "question" : "Sulfonamides can cause _______ in infants.",
                        "options" : [
                              "ototoxicity",
                              "kernicterus",
                              "grey baby syndrome",
                              "nephrotoxicity "
                        ],
                        "answer" : "kernicterus"
                  },
                  {
                        "title":"",  
                        "question" : "_______ is a side effect of sulfonamides so the medication should be taken at night.",
                        "options" : [
                              "Drowsiness",
                              "Confusion",
                              "Photosensitivity",
                              "Blindness"
                        ],
                        "answer" : "Photosensitivity"
                  },
                  {
                        "title":"",  
                        "question" : "Patients with _______ may show increased incidence of side effects.",
                        "options" : [
                              "alcoholism",
                              "diabetes",
                              "G6P deficiency",
                              "neuropathy"
                        ],
                        "answer" : "G6P deficiency"
                  },
                  {
                        "title":"",  
                        "question" : "Selective toxicity to sulfonamides in bacterial cells over mammalian cells occurs because humans lack _______ .",
                        "options" : [
                              "dihydrofolate reductase",
                              "cell walls",
                              "folic acid synthesis pathways",
                              "peptidoglycan"
                        ],
                        "answer" : "folic acid synthesis pathways"
                  },
                  {
                        "title":"",  
                        "question" : "A side effect of Bactrim that affects skin and mucous membranes is either _______ .",
                        "options" : [
                              "Eczema or Impetigo",
                              "Toxic Epidermal Necrolysis or Stevens Johnson Syndrome",
                              "Impetigo or Toxic Epidermal Necrolysis",
                              "Psoriasis or Stevens Johnson Syndrome"
                        ],
                        "answer" : "Toxic Epidermal Necrolysis or Stevens Johnson Syndrome"
                  },
                  {
                        "title":"",  
                        "question" : "If a patient is taking Bactrim and is G6DP deficient, _______ may be depleted and affect drug metabolism.",
                        "options" : [
                              "Folic acid",
                              "liver enzymes",
                              "white blood cells",
                              "lymph",
                              "Glutathione"
                        ],
                        "answer" : "Glutathione"
                  },
                  {
                        "title":"",  
                        "question" : "Sulfonamides target _______ to ultimately inhibit Folic Acid.",
                        "options" : [
                              "DHFR",
                              "DHPS",
                              "G6P",
                              "Folic Acid"
                        ],
                        "answer" : "DHPS"
                  }
            ],
             "reviewItems":[
                  {
                        "title": "Sulfonamides (Sulfamethoxazole, Sulfacetamide, Silver Sulfadiazine)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "sulfonamides.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicity", "content": ""}
                        ]
                  },
                  {
                        "title": "Trimethoprim (Related Compound: Pyrimethamine)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "trimethoprim.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "Target", "content": ""},
                              {"title": "MOA", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Spectrum", "content": ""},
                              {"title": "Toxicity", "content": ""}
                        ]
                  }
            ],                     
            "exampleReview":[
                  {
                        "title": "Sulfonamides (Sulfamethoxazole, Sulfacetamide, Silver Sulfadiazine)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "sulfonamides.PNG" },
                              {"title": "SAR", "content": "Essential components: [Benzene ring]. [Un-substituted amine para to sulfonamide]. [Sulfonamide para to amine]: -Sulfonamide must be un-ionized to cross bacterial cell membrane. -Sulfonamide must be ionized to interact with DHPS active site. -Disubstitution of sulfonamide abolishes activity (acidic hydrogen required). -Mono-substituted sulfonamide may increase activity (EWG & heterocycles favorable)"},
                              {"title": "Target", "content": "Dihydropteroate Synthase(DHPS)"},
                              {"title": "MOA", "content": "PABA mimic that competitively inhibits the synthesis of dihydrofolic acid from PABA. Bacteriostatic."},
                              {"title": "MOR", "content": "1. Decreased drug uptake (most common). 2. Overexpression of DHPS 3. Increase PABA in bacteria 4. Decrease affinity for sulfonamide by DHPS"},
                              {"title": "Spectrum", "content": "Broad Spectrum but use as monotherapy is rare"},
                              {"title": "Toxicity", "content": "Nephrotoxicity; Crystalluria, Rash, Photosensitivity, Stevens-Johnson Syndrome"}
                        ]
                  },
                  {
                        "title": "Trimethoprim (Related Compound: Pyrimethamine)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "trimethoprim.PNG" },
                              {"title": "SAR", "content": "-Removal of primary amine results in complete inactivity. -Removal of one or more methoxy groups on trimethoprim results in loss of activity to varying degrees."},
                              {"title": "Target", "content": "Dihydrofolate Reductase (DHFR)"},
                              {"title": "MOA", "content": "Inhibits a step of the recycling of the folate cofactor (dihydrofolate to tetrahydrofolate) for purine and thymidine biosynthesis. Binds with ~300x more affinity to bacteria vs. human DHFR. Bacteriostatic"},
                              {"title": "MOR", "content": "1. Overexpression of DHFR. 2. Decrease affinity for sulfonamide due to mutated enzyme."},
                              {"title": "Spectrum", "content": "Broad Spectrum. Used in synergy with sulfonamides because of resistance."},
                              {"title": "Toxicity", "content": "Hypersensitivity rash, Hyperkalemia, Hematologic effects"}
                        ]
                  }
            ]            
      },
      {
            "id": 12,
            "name": "DNA-Topo",
            "learnItems":[
                  {
                        "title":"Quinolones",  
                        "name" : "Hover over the Quinolones compound to view SAR.",
                        "imagePath" : "quinolones.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "Position 1",
                                    "y": 407,
                                    "x": 342,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Position 1: Nitrogen can allow substitutions of alkyl (Me, Et, cPr) or aryl (2,4-difluorophenyl) groups"
                              },
                              {
                                    "name": "Position 2",
                                    "y": 327,
                                    "x": 420,
                                    "size": 40,
                                    "color": "darkorange",
                                    "text": "Position 2: Can be either a carbon or nitrogen"
                              },
                              {
                                    "name": "Position 3",
                                    "y": 225,
                                    "x": 480,
                                    "size": 75,
                                    "color": "gold",
                                    "text": "Position 3: Must be unsubstituted carboxylic acid"
                              },
                              {
                                    "name": "Position 4",
                                    "y": 175,
                                    "x": 342,
                                    "size": 60,
                                    "color": "green",
                                    "text": "Position 4: Must be ketone"
                              },
                              {
                                    "name": "Position 6",
                                    "y": 253,
                                    "x": 166,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Position 6: Fluorine substitution increases activity and broadens spectrum"
                              },
                              {
                                    "name": "Position 7",
                                    "y": 333,
                                    "x": 162,
                                    "size": 40,
                                    "color": "purple",
                                    "text": "Position 7: Substitution with nitrogen containing heterocycles (piperazine ring) broadens spectrum; potential for zwitterion"
                              },
                              {
                                    "name": "Position 8",
                                    "y": 375,
                                    "x": 235,
                                    "size": 40,
                                    "color": "deeppink",
                                    "text": "Position 8: Substitution with small polar groups (OCH3, F, Cl) increases activity"
                              }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide3.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Ketone at position 4 is essential to bind to target."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide4.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "F at position 6 increases activity and broadens spectrum."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide5.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Methoxy substitution at position 8 increases activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide6.PNG",
                        "question" : "Which is the most active quinolone?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Moxifloxacin (compound 1) because the addition of methoxy at position 8 improves activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide7.PNG",
                        "question" : "What does the addition of the circled group result in?",
                        "options" : [
                              "Improves activity", 
                              "Increases half life",
                              "Broadens spectrum",
                              "Decreases resistance"
                        ],
                        "answer" : "Broadens spectrum",
                        "explanation" : "Because it increases activity against pseudomonas."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide8.PNG",
                        "question" : "What can the circled moities lead to?",
                        "options" : [
                              "Broadening spectrum", 
                              "Increasing half life",
                              "Decreasing resistance",
                              "Chelation with metals"
                        ],
                        "answer" : "Chelation with metals",
                        "explanation" : "Chelation with metals can reduce oral absorption; do not take with antacids, mineral supplements, or dairy products."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide9.PNG",
                        "question" : "JT is a 4-year-old boy diagnosed with a gram-negative infection, which antibiotic do you NOT recommend?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Ciprofloxacin (Compound 2) should be recommended since quinolones can lead to tendon rupture in young children and should never be used first line."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide10.PNG",
                        "question" : "AM is diagnosed with a pseudomonal infection, which antibiotic do you recommend?",
                        "options" : [
                              "Compound 1", 
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Norfloxacin (Compound 2) contains piperazine ring, which gives it anti-pseudomonal activity."
                  }
            ],
            "testItems":[
                  {
                        "title":"",  
                        "question" : "Quinolones have a side effect of _______ due to a high pka of the acid.",
                        "options" : [
                              "UTI",
                              "Crystalluria",
                              "Cystitis",
                              "BPH"
                        ],
                        "answer" : "Crystalluria"
                  },
                  {
                        "title":"",  
                        "question" : "A serious side effect of quinolones that have given it a black box warning is _______ .",
                        "options" : [
                              "myelosuppression",
                              "myalgia",
                              "muscular dystrophy",
                              "tendon rupture"
                        ],
                        "answer" : "tendon rupture"
                  },
                  {
                        "title":"",  
                        "question" : "Combination with _______ cause synergistic inhibition of GABA receptors and neuroexcitatory activity.",
                        "options" : [
                              "Narcotics",
                              "Antidepressants",
                              "Antipsychotics",
                              "NSAIDs"
                        ],
                        "answer" : "NSAIDs"
                  },
                  {
                        "title":"",  
                        "question" : "A side effect of quinolones is _______ so caution should be taken with heart condition.",
                        "options" : [
                              "Bradycardia",
                              "QT prolongation",
                              "ST segment prolongation",
                              "Hypertension"
                        ],
                        "answer" : "QT prolongation"
                  },
                  {
                        "title":"",  
                        "question" : "Fluoroquinolones should be taken in the evening due to _______ .",
                        "options" : [
                              "drowsiness",
                              "overactive bladder",
                              "photosensitivity"
                        ],
                        "answer" : "photosensitivity"
                  }
            ],
             "reviewItems":[
                   {
                        "title": "Fluoroquinolones SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fluoroquinolones.PNG" },
                              {"title": "Position 1", "content": ""},
                              {"title": "Position 2", "content": ""},
                              {"title": "Position 3", "content": ""},
                              {"title": "Position 4", "content": ""},
                              {"title": "Position 5", "content": ""},
                              {"title": "Position 6", "content": ""},
                              {"title": "Position 7", "content": ""},
                              {"title": "Position 8", "content": ""}
                        ]
                  },
                  {
                        "title": "Fluoroquinolones Info.",  
                        "sections" : [
                              {"title": "Examples", "content": ""},
                              {"title": "Mechanism of Action & Target", "content": ""},
                              {"title": "Mechanism of Resistance", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicities/DDI’s", "content": ""}
                        ]
                  }                  
            ],                     
            "exampleReview":[
                  {
                        "title": "Fluoroquinolones SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "fluoroquinolones.PNG" },
                              {"title": "Position 1", "content": "Nitrogen can allow substitutions of alkyl (Me, Et, cPr) or aryl (2,4-difluorophenyl) groups"},
                              {"title": "Position 2", "content": "Can be either a carbon or nitrogen"},
                              {"title": "Position 3", "content": "Must be unsubstituted carboxylic acid"},
                              {"title": "Position 4", "content": "Must be ketone"},
                              {"title": "Position 6", "content": "Fluorine substitution increases activity and broadens spectrum"},
                              {"title": "Position 7", "content": "Substitution with nitrogen containing heterocycles (piperazine ring) broadens spectrum; potential for zwitterion"},
                              {"title": "Position 8", "content": "Substitution with small polar groups (OCH3, F, Cl) increases activity"}
                        ]
                  },
                  {
                        "title": "Fluoroquinolones Info.",  
                        "sections" : [
                              {"title": "Examples", "content": "(Ciprofloxacin, Levofloxacin, Moxifloxacin)"},
                              {"title": "Mechanism of Action & Target", "content": "MOA: Irreversibly inhibits topoisomerase (DNA gyrase) enzymes, which inhibits relaxation of supercoiled DNA and promotes breakage of double stranded DNA. Bactericidal. Target: Topoisomerase II (DNA Gyrase)"},
                              {"title": "Mechanism of Resistance", "content": "1. Mutation to the quinolone-resistance determining region (QRDR) of gyrase that affects the binding of fluoroquinolones. 2. Active drug efflux. 3. Decrease drug uptake (reduced permeability)"},
                              {"title": "Indication/Spectrum", "content": "Broad spectrum (increases with increasing generation)"},
                              {"title": "Toxicities/DDI’s", "content": "Tendon rupture, QT prolongation, Phototoxicity. Rashes, Peripheral neuropathy. DDI: Chelation with cations, synergistic inhibition of GABA receptor with NSAIDs"}
                        ]
                  }
            ]            
      },
      {
            "id": 13,
            "name": "30S-PB-Inhibitors",
            "learnItems":[
                  {
                        "title":"Aminoglycosides",  
                        "name" : "Hover over the Aminoglycosides compound to view SAR.",
                        "imagePath" : "aminoglycosides.PNG",
                        "imgWidth" : 450,
                        "imgPadding" : 200,
                        "compoundHotspots" : [
                              {
                                    "name": "Ring 1",
                                    "y": 241,
                                    "x": 275,
                                    "size": 80,
                                    "color": "blue",
                                    "text": "Ring 1: The amine can be methylated or changed to a hydroxyl group, but its removal will abolish activity."
                              },
                              {
                                    "name": "Ring 2",
                                    "y": 300,
                                    "x": 416,
                                    "size": 80,
                                    "color": "red",
                                    "text": "Ring 2: Many modifications are possible, for example the 3- amine can be substituted or acylated."
                              },
                              {
                                    "name": "Ring 3",
                                    "y": 231,
                                    "x": 547,
                                    "size": 90,
                                    "color": "green",
                                    "text": "Ring 3: -Crucial for broad-spectrum activity. -First target of inactivating enzymes. -The 2-, 3-, 4- hydroxyl groups are not essential for activity. -Methylation of the amine will retain activity and will lower susceptibility to transferases. -All substitutions must be equatorial"
                              }
                        ]
                  },
                  {
                        "title":"Tetracyclines",  
                        "name" : "Hover over the Tetracyclines compound to view SAR.",
                        "imagePath" : "tetracyclines.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 150,
                        "compoundHotspots" : [
                              {
                                    "name": "Position 1",
                                    "y": 315,
                                    "x": 426,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Positions 1, 10, 11, 12 and 12a: any changes will completely abolish activity, even changes in the stereochemical configuration."
                              },
                              {
                                    "name": "Position 2",
                                    "y": 285,
                                    "x": 507,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Position 2: Any changes leads to decreased activity, even substitution to the amide."
                              },
                              {
                                    "name": "Position 4",
                                    "y": 170,
                                    "x": 438,
                                    "size": 35,
                                    "color": "blue",
                                    "text": "Position 3: Amine in the α-position is essential, but monosubstitution is also active."
                              },
                              {
                                    "name": "Position 5",
                                    "y": 188,
                                    "x": 348,
                                    "size": 35,
                                    "color": "green",
                                    "text": "Position 5: R4 can be a hydroxyl, keto group or a hydrogen, and all are active."
                              },
                              {
                                    "name": "Position 6",
                                    "y": 184,
                                    "x": 282,
                                    "size": 35,
                                    "color": "gold",
                                    "text": "Position 6: Both substitutions (R2 and R3) are not necessary."
                              },
                              {
                                    "name": "Position 7",
                                    "y": 194,
                                    "x": 208,
                                    "size": 30,
                                    "color": "darkorange",
                                    "text": "Position 7: Cl, F, Br, NO2 and a tertiary amine are all active."
                              },
                              {
                                    "name": "Position 8",
                                    "y": 216,
                                    "x": 162,
                                    "size": 30,
                                    "color": "purple",
                                    "text": "Position 8: Any electron withdrawing or donating group is still active"
                              },
                              {
                                    "name": "Position 9",
                                    "y": 274,
                                    "x": 164,
                                    "size": 30,
                                    "color": "grey",
                                    "text": "Position 9: Bulky substitution decreases resistance."
                              },
                              {
                                    "name": "Position 10",
                                    "y": 315,
                                    "x": 211,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Positions 1, 10, 11, 12 and 12a: any changes will completely abolish activity, even changes in the stereochemical configuration."
                              },
                              {
                                    "name": "Position 11",
                                    "y": 315,
                                    "x": 284,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Positions 1, 10, 11, 12 and 12a: any changes will completely abolish activity, even changes in the stereochemical configuration."
                              },
                              {
                                    "name": "Position 12",
                                    "y": 315,
                                    "x": 355,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Positions 1, 10, 11, 12 and 12a: any changes will completely abolish activity, even changes in the stereochemical configuration."
                              },
                              {
                                    "name": "Position 12a",
                                    "y": 315,
                                    "x": 355,
                                    "size": 30,
                                    "color": "deeppink",
                                    "text": "Positions 1, 10, 11, 12 and 12a: any changes will completely abolish activity, even changes in the stereochemical configuration."
                              }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide4.PNG",
                        "question" : "Will the following change increase or decrease chemical stability?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Replacement of OH with H at position 6 makes the compound more stable."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide5.PNG",
                        "question" : "Will the following change increase or decrease bacterial resistance?",
                        "options" : [
                              "Increase", 
                              "Decrease"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Addition of bulky group protects the compound from inactivating enzymes."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide6.PNG",
                        "question" : "Which of the following binds to both the 30S and 50S ribosomal units?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Tobramycin (compound 2) is the only aminoglycoside that binds to both ribosomal units."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide7.PNG",
                        "question" : "Which of the following is only used topically?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Neomycin (Compound 1) because only used topically due to nephrotoxicity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide8.PNG",
                        "question" : "Which of the following does NOT bind to the 30S ribosomal unit?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Azithromycin (Compound 2) because Macrolides bind to the 50S ribosomal unit."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide9.PNG",
                        "question" : "Which of the following is NOT bactericidal?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 2",
                        "explanation" : "Tetracycline (Compound 2) because Tetracyclines are bacteriostatic."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide10.PNG",
                        "question" : "Which is less susceptible to bacterial resistance?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Tigecycline (Compound 3) because addition of bulky group to position 9."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide11.PNG",
                        "question" : "Which antibiotic is used primarily by IV injections?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Gentamicin (Compound 3) because Aminoglycosides are not orally absorbed."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide12.PNG",
                        "question" : "What is the main advantage of the circled group?",
                        "options" : [
                              "Retains activity",
                              "Increases half life", 
                              "Broadens spectrum",
                              "Decreases resistance"
                        ],
                        "answer" : "Decreases resistance",
                        "explanation" : "Less spots for inactivating enzymes to act."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide13.PNG",
                        "question" : "What is the importance of retaining the stereochemistry of the circled group?",
                        "options" : [
                              "Retains activity",
                              "Increases half life", 
                              "Broadens spectrum",
                              "Decreases resistance"
                        ],
                        "answer" : "Retains activity",
                        "explanation" : "Essential for activity."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide14.PNG",
                        "question" : "Which reaction of this compound leads to a toxic product?",
                        "options" : [
                              "Decompositon in acidic medium",
                              "Decompositon in basic medium", 
                              "Chelation",
                              "Epimerization"
                        ],
                        "answer" : "Decompositon in acidic medium",
                        "explanation" : "Nephrotoxic product."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide15.PNG",
                        "question" : "Which reactions inactivate this compound?",
                        "options" : [
                              "Decompositon in acidic medium & Chelation",
                              "Decompositon in basic medium & Epimerization", 
                              "Decompositon in basic medium & Chelation",
                              "Decompositon in acidic medium & Epimerization"
                        ],
                        "answer" : "Decompositon in basic medium & Epimerization",
                        "explanation" : "No explanation provided."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide16.PNG",
                        "question" : "Carly Sandbergin is going on vacation to sunny Florida, which antibiotic(s) should she avoid?",
                        "options" : [
                              "Compound 1",
                              "Compound 2", 
                              "Compound 3",
                              "Compound 1 & 2",
                              "Compound 2 & 3"
                        ],
                        "answer" : "Compound 1 & 2",
                        "explanation" : "Doxycycline (Compound 1) & Ciprofloxacin (Compound 2) because both tetracyclines and quinolones can lead to phototoxicity."
                  }
            ],
            "testItems":[
                 {
                        "title":"",  
                        "question" : "Toxicity to tetracyclines include chelation with _______ which can affect teeth and bone formation.",
                        "options" : [
                              "magnesium",
                              "sodium",
                              "potassium",
                              "calcium"
                        ],
                        "answer" : "calcium"
                  },
                  {
                        "title":"",  
                        "question" : "Tetracyclines can cause drug induced _______ so caution in renally impaired patients.",
                        "options" : [
                              "Renal Fanconi syndrome",
                              "renal failure",
                              "kidney stones",
                              "CKD"
                        ],
                        "answer" : "Renal Fanconi syndrome"
                  },
                  {
                        "title":"",  
                        "question" : "Contraindicated in patients less than eight years old or _______.",
                        "options" : [
                              "Diabetic",
                              "asthmatic",
                              "pregnant",
                              "lactating"
                        ],
                        "answer" : "pregnant"
                  },
                  {
                        "title":"",  
                        "question" : "Aminoglycosides have toxicity problems such as ototoxicity and _______ .",
                        "options" : [
                              "neurotoxicity",
                              "retinal toxicity",
                              "nephrotoxocity",
                              "hepatotoxicity"
                        ],
                        "answer" : "nephrotoxocity"
                  },
                  {
                        "title":"",  
                        "question" : "Can be deadly due to _______ failure.",
                        "options" : [
                              "renal",
                              "liver",
                              "respiratory"
                        ],
                        "answer" : "respiratory"
                  },
                  {
                        "title":"",  
                        "question" : "Prolonged exposure to aminoglycosides can cause toxic side effects so “ _______ ” is used to give the dose once daily.",
                        "options" : [
                              "Extended interval dosing",
                              "pulse dosing",
                              "dosing pump"
                        ],
                        "answer" : "pulse dosing"
                  },
                  {
                        "title":"",  
                        "question" : "The most toxic aminoglycoside that is used therapeutically is _______ but it is only used _______ .",
                        "options" : [
                              "Bleomycin, Orally",
                              "Bleomycin, Intravenously",
                              "Neomycin, Topically",
                              "Neomycin, Intravenously",
                              "Streptomycin, Orally",
                              "Streptomycin, Topically"
                        ],
                        "answer" : "Neomycin, Topically"
                  },
                  {
                        "title":"",  
                        "question" : "Two disorders that put patients at higher risk for neurotoxicity with aminoglycosides are Myasthenia Gravis and _______ .",
                        "options" : [
                              "Parkinson’s disease",
                              "epilepsy",
                              "dementia",
                              "multiple sclerosis"
                        ],
                        "answer" : "Parkinson’s disease"
                  }
            ],
             "reviewItems":[
                   {
                        "title": "Aminoglycosides SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "aminoglycosides.PNG" },
                              {"title": "Ring 1", "content": ""},
                              {"title": "Ring 2", "content": ""},
                              {"title": "Ring 3", "content": ""},
                              {"title": "Polycationic at physiological pH", "content": ""}
                        ]
                  },
                  {
                        "title": "Aminoglycosides Info.",  
                        "sections" : [
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Tetracyclines SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "tetracyclines.PNG" },
                              {"title": "Positions 1, 10, 11, 12, & 12a", "content": ""},
                              {"title": "Position 2", "content": ""},
                              {"title": "Position 4", "content": ""},
                              {"title": "Position 5", "content": ""},
                              {"title": "Position 6", "content": ""},
                              {"title": "Position 7", "content": ""},
                              {"title": "Position 8", "content": ""},
                              {"title": "Position 9", "content": ""},
                              {"title": "Warhead", "content": ""}
                        ]
                  },
                   {
                        "title": "Tetracyclines Info.",  
                        "sections" : [
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  }
            ],                     
            "exampleReview": [
                  {
                        "title": "Aminoglycosides SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "aminoglycosides.PNG" },
                              {"title": "Ring 1", "content": "-Crucial for broad-spectrum activity. -First target of inactivating enzymes. -The 2-, 3-, 4- hydroxyl groups are not essential for activity. -Methylation of the amine will retain activity and will lower susceptibility to transferases. -All substitutions must be equatorial."},
                              {"title": "Ring 2", "content": "Many modifications are possible, for example the 3- amine can be substituted or acylated."},
                              {"title": "Ring 3", "content": "The amine can be methylated or changed to a hydroxyl group, but its removal will abolish activity."},
                              {"title": "Polycationic at physiological pH", "content": "Poor oral absorption"}
                        ]
                  },
                  {
                        "title": "Aminoglycosides Info.",  
                        "sections" : [
                              {"title": "MOA & Target", "content": "-Binds irreversibly to the 30S ribosomal subunit and changes to the “A” site. -Enters cell by binding negatively charged phospholipids and entering via electron transport linked system -> method can be antagonized by divalent cations. Bactericidal. Target: 30S"},
                              {"title": "MOR", "content": "1. Decreased permeation of aminoglycosides (loss of porin). 2. Bacteria produce enzymes that acetylate or phosphorylate aminoglycosides’ hydroxyl groups to make aminoglycoside inactive. 3. Ribosomal mutations."},
                              {"title": "Indication/Spectrum", "content": "Very broad spectrum, but better against G-. Used mainly against G- bacilli AEROBES."},
                              {"title": "Toxicity/DDI", "content": "Nephrotoxicity, Ototoxicity, Neuromuscular blockade (muscular paralysis)"}
                        ]
                  },
                  {
                        "title": "Tetracyclines SAR",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "tetracyclines.PNG" },
                              {"title": "Positions 1, 10, 11, 12, & 12a", "content": "Any changes will completely abolish activity, even changes in the stereochemical configuration. Resonance between position 10 and 11 needed for activity."},
                              {"title": "Position 2", "content": "Any changes leads to decreased activity, even substitution to the amide"},
                              {"title": "Position 4", "content": "Amine in the α-position is essential, but monosubstitution is also active"},
                              {"title": "Position 5", "content": "R4 can be a hydroxyl, keto group or a hydrogen, and all are active"},
                              {"title": "Position 6", "content": "Both substitutions (R2 and R3) are not necessary"},
                              {"title": "Position 7", "content": "Cl, F, Br, NO2 and a tertiary amine are all active"},
                              {"title": "Position 8", "content": "Any electron withdrawing or donating group is still active"},
                              {"title": "Position 9", "content": "bulky substitution decreases resistance"},
                              {"title": "Warhead", "content": "Resonance between 11 and 12"}
                        ]
                  },
                   {
                        "title": "Tetracyclines Info.",  
                        "sections" : [
                              {"title": "MOA & Target", "content": "Binds reversibly to 30S ribosomal subunit at the A site, preventing attachment of tRNA – leading to termination of translation. Bacteriostatic. Target: 30S"},
                              {"title": "MOR", "content": "1. Develops efflux pumps. 2. Genes for tet-resistance transmitted by plasmids. 3. Enzymatic modification of antibiotic preventing binding to 30S."},
                              {"title": "Indication/Spectrum", "content": "Broad spectrum: G+, G-, aerobic and anaerobic"},
                              {"title": "Toxicity/DDI", "content": "Phototoxicity, Inhibition of bone growth, nephrotoxic, hepatotoxic , stains teeth. DDI: chelation with cations (dairy products, antacids, supplements)"}
                        ]
                  }
            ]            
      },
      {
            "id": 14,
            "name": "50S-PB-Inhibitors",
            "learnItems":[
                  {
                        "title":"Macrolides",  
                        "name" : "Hover over the Macrolides compound to view SAR.",
                        "imagePath" : "macrolides-sar.PNG",
                        "imgWidth" : 450,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Sugar",
                                    "y": 401,
                                    "x": 392,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Macrolides contain one or two sugars usually desosamine and/or cladinose."
                              },
                              {
                                    "name": "Sugar",
                                    "y": 262,
                                    "x": 465,
                                    "size": 60,
                                    "color": "red",
                                    "text": "Macrolides contain one or two sugars usually desosamine and/or cladinose."
                              },
                              {
                                    "name": "Lactone Ring ",
                                    "y": 246,
                                    "x": 278,
                                    "size": 80,
                                    "color": "blue",
                                    "text": "Large lactone ring (12, 14, or 16 membered ring)."
                              }
                        ]
                  },
                  {
                        "title":"Ketolides",  
                        "name" : "Hover over the Ketolides compound to view SAR.",
                        "imagePath" : "ketolides-sar.PNG",
                        "imgWidth" : 400,
                        "imgPadding" : 160,
                        "compoundHotspots" : [
                              {
                                    "name": "3-keto functional group",
                                    "y": 393,
                                    "x": 354,
                                    "size": 30,
                                    "color": "red",
                                    "text": "3-keto functional group replaces L-cladinose sugar of erythromycin A: Restores activity against bacteria with inducible resistance mediated by Erm, and enhances activity against streptococci with Mef-mediated macrolide efflux"
                              },
                              {
                                    "name": "Carbamate Side Chain",
                                    "y": 235,
                                    "x": 145,
                                    "size": 80,
                                    "color": "blue",
                                    "text": "Carbamate Side Chain Addition: Promotes activity against both erythromycin-sensitive and erythromycin-resistant bacteria by introducing an interaction with domain II of the 23S rRNA."
                              }
                        ]
                  },
                  {
                        "title":"Lincosamides",  
                        "name" : "Hover over the Lincosamides compound to view SAR.",
                        "imagePath" : "lincosamides-sar.PNG",
                        "imgWidth" : 450,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Eight Carbon Sugar",
                                    "y": 209,
                                    "x": 450,
                                    "size": 130,
                                    "color": "red",
                                    "text": "Eight Carbon Sugar"
                              },
                              {
                                    "name": "Amide bond",
                                    "y": 228,
                                    "x": 278,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "Amide bond."
                              }
                        ]
                  },
                  {
                        "title":"Streptogramins",  
                        "name" : "Hover over the Streptogramins compound to view SAR.",
                        "imagePath" : "streptogramins-sar.PNG",
                        "imgWidth" : 700,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Type A: Quinupristin",
                                    "y": 275,
                                    "x": 257,
                                    "size": 175,
                                    "color": "red",
                                    "text": "Type A: Quinupristi - Type A & B used together synergistically"
                              },
                              {
                                    "name": "Type B: Dalfopristin",
                                    "y": 260,
                                    "x": 685,
                                    "size": 175,
                                    "color": "blue",
                                    "text": "Type B: Dalfopristin - Type A & B used together synergistically"
                              }
                        ]
                  },
                  {
                        "title":"Chloramphenicol",  
                        "name" : "Hover over the Chloramphenicol compound to view SAR.",
                        "imagePath" : "chloramphenicol-sar.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 130,
                        "compoundHotspots" : [
                              {
                                    "name": "Nitro group",
                                    "y": 223,
                                    "x": 164,
                                    "size": 40,
                                    "color": "red",
                                    "text": "Nitro group: can be replaced with other EWG, but activity decreases"
                              },
                              {
                                    "name": "Aromatic ring",
                                    "y": 223,
                                    "x": 283,
                                    "size": 60,
                                    "color": "darkorange",
                                    "text": "Aromatic ring: essential for activity"
                              },
                              {
                                    "name": "Chlorines",
                                    "y": 181,
                                    "x": 617,
                                    "size": 40,
                                    "color": "green",
                                    "text": "Chlorines: can be removed or replaced with other halogens, but activity decreases"
                              },
                              {
                                    "name": "R, R stereoisomer",
                                    "y": 223,
                                    "x": 409,
                                    "size": 40,
                                    "color": "blue",
                                    "text": "R, R stereoisomer: essential for activity"
                              }
                        ]
                  },
                  {
                        "title":"Oxazolidinones",  
                        "name" : "Hover over the Oxazolidinones compound to view SAR.",
                        "imagePath" : "oxazolidinones-sar.PNG",
                        "imgWidth" : 500,
                        "imgPadding" : 100,
                        "compoundHotspots" : [
                              {
                                    "name": "Oxazolidinone ring",
                                    "y": 155,
                                    "x": 410,
                                    "size": 70,
                                    "color": "red",
                                    "text": "Oxazolidinone ring"
                              }
                        ]
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide8.PNG",
                        "question" : "Will the following change increase or decrease chemical stability?",
                        "options" : [
                              "Increase",
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "Replacement of OH with OCH3 reduces acid-catalyzed degradation."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide9.PNG",
                        "question" : "Will the following change increase or decrease acid stability?",
                        "options" : [
                              "Increase",
                              "Decrease"
                        ],
                        "answer" : "Increase",
                        "explanation" : "15 member ring (with no ketone) increases acid stability and permits accumulation of azithromycin in the cell."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Activity Change",
                        "imagePath" : "slide10.PNG",
                        "question" : "Will the following change increase or decrease activity?",
                        "options" : [
                              "Increase",
                              "Decrease"
                        ],
                        "answer" : "Decrease",
                        "explanation" : "Cl increases lipophilicity and has better oral absorption."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide11.PNG",
                        "question" : "Which compound is less susceptible to bacteria resistance?",
                        "options" : [
                              "Compound 1",
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Telithromycin (Compound 1) because the addition of 3-keto group and carbamate side chain."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Compare Compounds",
                        "imagePath" : "slide12.PNG",
                        "question" : "Which of the following is NOT bacteriostatic?",
                        "options" : [
                              "Compound 1",
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Gentamicin (Compound 1) because Aminoglycosides are bactericidal."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Choose the Correct Answer",
                        "imagePath" : "slide13.PNG",
                        "question" : "Gray Baby Syndrome results from inability to produce which metabolite?",
                        "options" : [
                              "Dechlorination",
                              "N-reduction",
                              "3-O-glucuronidation"
                        ],
                        "answer" : "3-O-glucuronidation",
                        "explanation" : "No explanation provided."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide14.PNG",
                        "question" : "Lucille Mangonzy is experiencing diarrhea after taking her antibiotic, which compound did she most likely take?",
                        "options" : [
                              "Compound 1",
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 3",
                        "explanation" : "Clindamycin (Compound 3) has highest incidence of pseudomembranous colitis."
                  },
                  {
                        "title":"SAR Practice Problem",  
                        "name" : "Clinical Case Study",
                        "imagePath" : "slide15.PNG",
                        "question" : "Which compound is less susceptible to bacteria resistance?",
                        "options" : [
                              "Compound 1",
                              "Compound 2",
                              "Compound 3"
                        ],
                        "answer" : "Compound 1",
                        "explanation" : "Chloramphenicol (Compound 1) has a major toxicity of aplastic anemia."
                  }
            ],
            "testItems":[
                 {
                        "title":"",  
                        "question" : "Macrolides have many DDI’s with other drugs such as _______ .",
                        "options" : [
                              "ACE inhibitors",
                              "NSAIDs",
                              "Beta Blockers",
                              "statins"
                        ],
                        "answer" : "statins"
                  },
                  {
                        "title":"",  
                        "question" : " _______ has evidence for liver transplant.",
                        "options" : [
                              "Dirithromycin",
                              "Azithromycin",
                              "Erythromycin",
                              "Telithromycin"
                        ],
                        "answer" : "Telithromycin"
                  },
                  {
                        "title":"",  
                        "question" : "The macrolide ________ is a prodrug activated by hydrolysis.",
                        "options" : [
                              "Dirithromycin",
                              "Telithromycin",
                              "Erythromycin",
                              "Azithromycin"
                        ],
                        "answer" : "Dirithromycin"
                  },
                  {
                        "title":"",  
                        "question" : "Synercid, a combination including quinupristin and dalfopristin, can only be administered with _______.",
                        "options" : [
                              "orally",
                              "IV",
                              "intrathecal",
                              "injection"
                        ],
                        "answer" : "IV"
                  },
                  {
                        "title":"",  
                        "question" : "High levels of chloramphenicol may cause fatal neonatal toxicity and _______ .",
                        "options" : [
                              "thrombocytopenia",
                              "hemolytic anemia",
                              "aplastic anemia",
                              "leukemia"
                        ],
                        "answer" : "aplastic anemia"
                  },
                  {
                        "title":"",  
                        "question" : "A side effect of Streptogramin is _______ .",
                        "options" : [
                              "muscle/joint pain",
                              "myalgia",
                              "constipation",
                              "neuropathy"
                        ],
                        "answer" : "muscle/joint pain"
                  },
                  {
                        "title":"",  
                        "question" : "Azithromycin has a caution for patients as risk of _______ .",
                        "options" : [
                              "Diabetes",
                              "Heart failure",
                              "QT prolongation",
                              "Liver failure"
                        ],
                        "answer" : "QT prolongation"
                  },
                  {
                        "title":"",  
                        "question" : " _______ has the least potential for Cyp450 inhibition.",
                        "options" : [
                              "Azithromycin",
                              "Erythromycin",
                              "Telithromycin",
                              "Bleomycin"
                        ],
                        "answer" : "Azithromycin"
                  }
            ],
             "reviewItems":[
                   {
                        "title": "Macrolides (Erythromycin, Clarithromycin, Azithromycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "macrolides.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Ketolides (Telithromycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "ketolides.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Lincosamides (Clindamycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "lincosamides.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Streptogramins (Synercid, Pristamycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "streptogramins.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Chloramphenicol",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "chloramphenicol.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  },
                  {
                        "title": "Oxazolidiones (Linezolid, Tedizolid)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "oxazolidiones.PNG" },
                              {"title": "SAR", "content": ""},
                              {"title": "MOA & Target", "content": ""},
                              {"title": "MOR", "content": ""},
                              {"title": "Indication/Spectrum", "content": ""},
                              {"title": "Toxicity/DDI", "content": ""}
                        ]
                  }
            ],                     
            "exampleReview": [
                  {
                        "title": "Macrolides (Erythromycin, Clarithromycin, Azithromycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "macrolides.PNG" },
                              {"title": "SAR", "content": "-Large lactone ring (12, 14, or 16 membered ring). -Contain one or two sugars usually desosamine and/or cladinose. -Connection via ester bond. -Synthetic modifications made on the sugar and the 6 and 12-OH."},
                              {"title": "MOA & Target", "content": "Inhibit elongation, promote dissociation of peptidyl t-RNA before completion of peptide synthesis by blocking exit tunnel. Reversible binding. Bacteriostatic."},
                              {"title": "MOR", "content": "Methylation A2058 by ermC"},
                              {"title": "Indication/Spectrum", "content": "100x more affinity for gram positive vs gram negative"},
                              {"title": "Toxicity/DDI", "content": "QT prolongation, hepatitis, p450 inhibitor (carbamazepines, benzodiazepines, warfarin, theophylline, prednisone, cyclosporins, statins)"}
                        ]
                  },
                  {
                        "title": "Ketolides (Telithromycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "ketolides.PNG" },
                              {"title": "SAR", "content": "-Replacement of the L-cladinose sugar of erythromycin A with a 3-keto functional group: Restores activity against bacteria with inducible resistance mediated by Erm, and enhances activity against streptococci with Mef-mediated macrolide efflux. -Addition of a carbamate side chain: Promotes activity against both erythromycin-sensitive and erythromycin-resistant bacteria by introducing an interaction with domain II of the 23S rRNA."},
                              {"title": "MOA & Target", "content": "Inhibit elongation, promote dissociation of peptidyl t-RNA before completion of peptide synthesis by blocking exit tunnel. Reversible binding. Increased affinity for ribosome (2 binding sites for 23 rRNA). Bacteriostatic"},
                              {"title": "MOR", "content": "Methylation A2058 by ermC"},
                              {"title": "Indication/Spectrum", "content": "Good gram positive"},
                              {"title": "Toxicity/DDI", "content": "QT prolongation, hepatitis, p450 inhibitor (carbamazepines, benzodiazepines, warfarin, theophylline, prednisone, cyclosporins, statins)"}
                        ]
                  },
                  {
                        "title": "Lincosamides (Clindamycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "lincosamides.PNG" },
                              {"title": "SAR", "content": "-Eight carbon sugar. -Amide bond."},
                              {"title": "MOA & Target", "content": "Reversibly binds to the 23S portion of 50S, block translocation of tRNA from A site to P site, blocks elongation. Bacteriostatic."},
                              {"title": "MOR", "content": "1. Target-site modification by methylation  of the 23S ribosomal target site, encoded by the erm(B) gene and prevents the binding of the antibiotic to its ribosomal target"},
                              {"title": "Indication/Spectrum", "content": "anaerobic gram positive and negative"},
                              {"title": "Toxicity/DDI", "content": "GI, rashes, pseudomembranous colitis"}
                        ]
                  },
                  {
                        "title": "Streptogramins (Synercid, Pristamycin)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "streptogramins.PNG" },
                              {"title": "SAR", "content": "None"},
                              {"title": "MOA & Target", "content": "Dalfopristin: irreversibly binds to 23S portion of the 50S (blocks the binding of aminoacyl-tRNA). Quinupristin: irreversibly binds to a nearby site on the 50S (inhibits peptide bond formation and elongation). Synergism. Conformational change of the ribosome and enhance the binding of quinupristin. Bactericidal together. Bacteriostatic alone. Target: 23S (D), 50S (Q); P site."},
                              {"title": "MOR", "content": "(2) target-site modification by methylation  of the 23S ribosomal target site, encoded by the erm(B) gene and prevents the binding of the antibiotic to its ribosomal target. (3) through efflux of the antibiotic. (4) Enzymatic inactivation of drug."},
                              {"title": "Indication/Spectrum", "content": "Gram positive. (Too big to enter gram negative)."},
                              {"title": "Toxicity/DDI", "content": "Muscle/joint pain, infusion related events (pain/thrombophlebitis). Cyp3A4 inhibitor so DDIs, myalgia and arthralgia"}
                        ]
                  },
                  {
                        "title": "Chloramphenicol",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "chloramphenicol.PNG" },
                              {"title": "SAR", "content": "-Nitro group: can be replaced with other EWG, but activity decreases. -Aromatic ring: essential for activity. -Chlorines: can be removed or replaced with other halogens, but activity decreases. -R, R stereoisomer: essential for activity."},
                              {"title": "MOA & Target", "content": "Reversibly Inhibits peptidyl transferase reaction (blocks peptide elongation), competes for macrolide and clindamycin binding. Bacteriostatic (bacteriocidal to influenzae)."},
                              {"title": "MOR", "content": "1. Plasmid-encoded acetyltransferase that inactivates drug. 2. Chloramphenicol aetyltransferase (CAT)."},
                              {"title": "Indication/Spectrum", "content": "Broad (gram positive, gram negative, anaerobes and atypicals)"},
                              {"title": "Toxicity/DDI", "content": "Significant toxicity, so rarely used. Hemolytic anemia (GSH reasoning), mammalian mitochondrial protein synthesis can be inhibited (erythrolpoietic cells highly sensitive)"}
                        ]
                  },
                  {
                        "title": "Oxazolidiones (Linezolid, Tedizolid)",  
                        "sections" : [
                              {"title": "Compound", "imagePath": "oxazolidiones.PNG" },
                              {"title": "SAR", "content": "-Oxazolidinone ring"},
                              {"title": "MOA & Target", "content": "Binds to alt. site on 50S from MLS drugs to prevent initiation complex formation.‘cidal for streptococci, ‘static for staphylococci and enterococci."},
                              {"title": "MOR", "content": "Mutations on 23S rRNA binding site"},
                              {"title": "Indication/Spectrum", "content": "Gram positive only (similar to vanco)"},
                              {"title": "Toxicity/DDI", "content": "MAO inhibitors so not with SSRIs, bone marrow suppression, mitochondrial toxicity"}
                        ]
                  }
            ]            
      }
]